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ABSTRACT
SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF METAL
COMPLEXES FOR SELECTIVE TARGETING AND ANTI-PROLIFERATIVE
EFFECT ON CANCER CELLS AND THEIR HYDROGEN EVOLUTION
CATALYTIC PROPERTIES
Nicholas Vishnosky
November 19, 2018
Bis-thiosemicarbazones (BTSC) and their metal chelates have properties that are
useful in several different scientific fields. These systems have already received attention
in major fields of biology and engineering. Hydrogen evolution reaction (HER) catalysts
need to be cheap and operate under minimal overpotentials with a long lifetime. The
treatment of cancer requires, novel agents that have potent cytotoxic activity against
cancer cells while displaying minimal side effects. In this dissertation the modular
synthesis of these bis-thiosemicarbazone systems is utilized to regulate the redox
chemistry for employment in the desired sector of chemistry. The ligand and metal
chelates synthesized were characterized via cyclic voltammetry, NMR, UV-visible
spectroscopy, FT-IR, EPR, and single crystal X-ray crystallography. The first generation
replaced the pendent amine functionality of BTSCs with an alkoxy group. This
replacement allowed for the structure to retain its physical characteristics that make these
systems of interest in biological settings. However the change in functional group allows
for tuning of the reduction potential, which is crucial for their activity. The copper
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diacetyl-bis(4-methylthiosemicarbazonato) (CuATSM) analog lays 250 mV more anodic
for its CuII/I couple.
Immobilization of NiATSM (2), NiATSDM (28), and NiATSM-F6 (29) on a
glassy carbon electrode surface revealed that after reductive cycling, 200-300 cycles,
improved the overpotentials of 2 and 28 by 250 mV from 700 mV to 450 mV. The lack
of a dramatic effect for 29, is due to solid state interactions between molecules and
electrode surface. Raman spectroscopy and SEM reveal that 29, does not remain on the
electrode surface, whereas 2 and 28 undergo dynamic rearrangement to improve overall
performance.
A combination of both the pendant amine and alkoxy functionalities gave rise to
the a new BTSC analog which chelated Ni, Cu and Zn. The electrochemical
characterization revealed the copper chelates to have reduction potentials around 0.950 V
CuII/I. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays
showed high selectivity and potency with 50% growth inhibitory (GI50) concentrations
of 0.09 and 2.0 μM for carcinogenic and healthy cell lines respectively. Further the
National Cancer Institute (NCI) 60 profile demonstrates that the copper chelate is
effective against a wide variety of cancer types.
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CHAPTER I
INTRODUCTION
1.1 Scope of Dissertation
This dissertation describes a series of three studies on the synthesis,
characterization, and various applications of N2S2 chelates related to the well-known bisthiosemicarbazone (BTSC) diacetyl-bis(4-methylthiosemicarbazone), H2ATSM. These
studies include: 1) the synthesis and characterization of a new class of N2S2 chelates and
their Cu(II) complexes; 2) the synthesis and application of nickel(II) BTSCs as
heterogeneous catalysts for the hydrogen evolution reaction (HER); 3) the synthesis and
evaluation of hybrid N2S2 chelates and their metal complexes as anti-cancer therapeutics.
A comprehensive list of the 29 N2S2 compounds synthesized and evaluated in this
dissertation can be found in Figure 1-1.
New ligands and metal complexes developed in these studies were characterized
by nuclear magnetic resonance (1H NMR and 13C NMR), Fourier-transform infrared (FTIR), and UV-Vis spectroscopies, mass spectrometry (ESI-MS), elemental analysis, single
crystal x-ray crystallography, and cyclic voltammetry. Additionally, copper (II) complexes
were characterized by electron paramagnetic resonance (EPR) spectroscopy. For
compounds evaluated as heterogeneous HER catalysts additional characterization
techniques were employed. These include linear sweep voltammetry (LSV) for complexes
deposited on the electrode surface, Raman spectroscopy, scanning electron microscopy
(SEM), and electrical impedance frequency response analysis (FRA). Compounds
1

investigated as anti-cancer therapeutics were subjugated to dose response analysis from 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Compounds
19 and 21 were screened by the National Cancer Institute (NCI) against a set of 60 cell
lines to examine potency against a standardized set of a cell lines and cancer types.

Figure 1-1. Numbering scheme for all complexes.
2

Chapter 1 provides an overview of the dissertation and introduces previous
implementations of metal BTSC complexes in diagnostic imaging, anti-cancer
therapeutics, and homogeneous hydrogen evolution catalysis. Chapter 2 specifies the
experimental conditions, such as synthetic methodologies, yields, and characterization
techniques for the complexes in this dissertation. This chapter also describes conditions
used to determine electrochemical data, homogeneous catalysis conditions, and
heterogeneous catalysis characterization. Chapter 3 describes the syntheses and
characterization of a new class of N2S2 chelates related to BTSCs and their Cu(II)
complexes. The six new N,Nʹ-bis(alkylthiocarbamate)butane-2,3-diimine chelates
incorporate alkoxy alkyl chains derived from primary and secondary alcohols in place of
the extensively studied pendant amines. The reduction potential of the Cu(II) complexes is
tuned through the incorporation of the alkoxy functional group while maintaining the
structural integrity that confers biological effects of BTSCs. Crucially, the data learned
from this system allows for greater modulation of the ligand framework to tune the redox
chemistry for either HER or anti-cancer. Chapter 4 focuses on the immobilization of three
nickel (II) BSTC complexes on the glassy carbon electrodes as heterogeneous HER
catalysts. These studies revealed a high dependence on surface morphology and solid state
interactions that led to an improved electrode contact to reduce overpotential. Further, these
nickel (II) BTSC complexes were not covalently linked to the electrode surface which
allowed for dynamic reorganization on the electrode surface. Despite not being covalently
linked, the complexes displayed robust activity over extended cycling. In Chapter, 5 the
anti-cancer activity of new asymmetric chelates related to BTSCs and their metal
complexes are discussed. It was observed from the MTT assays and electrochemistry that
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there is a clear effect of structure on the compound’s anti-cancer activity. The reduction
potentials illuminated features that conferred the selectivity for cancer cells compared to
the healthy cells. Lastly, Chapter 6 contains concluding thoughts and future directions to
the research in Chapters 3 – 5.
1.2 Synthesis of BSTCs and Radioimaging Applications
A class of compounds that has been applied in varying fields are
thiosemicarbazides, RNHCSNHNH2. The thiosemicarbazide family has been well studied
in areas such as tuberculosis treatments,1-2 anti-cancer activity,3-5 and metal absorbents.6
These wide ranging abilities of the thiosemicarbazide family stem from its modular
synthesis,7 which enables alteration of the molecule to suit the needs of a given application.
Furthermore, the hydrazine functionality of the thiosemicarbazide is capable of undergoing
a condensation reaction with a dione to generate bis-thiosemicarbazones (BTSC).8-9 The
identity of the dione used can be varied to generate an extensive library of ligands that
chelate a vast variety of metals.8,10-21
Like their thiosemicarbazide precursors, BTSCs have been extensively studied for
applications across multiple disciplines of science, such as the treatment of
neurodegenerative diseases,22-26 selective imaging of hypoxia,21,27-33 and as catalysts for
the hydrogen evolution reaction (HER).10,12,34-35 The overarching similarity in these various
applications is the accessibility of the reduction potential of the metal complex.16 For
example, the HER requires a catalyst for the reduction of protons and hypoxia imaging
relies on a complex that changes oxidation state under low oxygen conditions, where cells
inherently are in a more reducing environment than normoxic conditions. Thus the ability
to tune the reduction potential of a compound is paramount to the success in these fields.
4

Overall the synthetic methodology for BTSCs involves the condensation of a
thiosemicarbazide with a dione. The manner of the condensation can be either symmetric,
Figure 1-2A, or non-symmetric, Figure 1-2B. The symmetric condensation maintains
equivalent R groups from the thiosemicarbazide, but allows for variation in the dione R
groups.

The

prototypical

example

of

this

is

pyruvaldehyde

bis(N4-methyl-

thiosemicarbazonato) (H2PTSM).36-37 The non-symmetric condensation route allows for a
finer tuning technique of either solubility, redox potential, or structure effects. For
example, Que et al.32 exploited this methodology to attach a –CH2CF3 functionality for
enhanced selectivity in cancer cell imaging.32

Figure 1-2. Modular synthesis of symmetric condensation (A) and asymmetric condensation (B)
of BTSCs

5

The modulation of reduction potential through variation of the BTSC ligand
framework is exemplified by comparison of CuATSM and glyoxal bis(N4-methylthiosemicarbazonato) copper(II) (CuGTSM), Figure 1-3. The only structural difference
between these two complexes is the backbone moiety in which CuATSM has a 2,3butylene bridge whereas CuGTSM has an ethylene linker. The difference in electron donor
ability of these substituents has a dramatic effect on the reduction potential. The CuII/I
couple for CuATSM occurs at –1.11 V vs. ferrocenium/ferrocene (Fc+/Fc0), whereas the
CuII/I potential for CuGTSM is observed 160 mV more anodic at –0.95 V.38 This difference
in potential is the reason for the different biological activity of these two compounds. Both
CuATSM and CuGTSM have been evaluated for hypoxia imaging via radiolabeling with
either

64

Cu or

62

Cu. The more difficult to reduce CuATSM is found to be selectively

retained in only hypoxic cells. The retention is based on the generation of a charged
complex that only occurs in hypoxic cell, which prevents diffusion of the Cu from the
cell.30 However, the more easily reduced CuGTSM, is reduced and retained in both
normoxic and hypoxic cells.30 This finding has led to the synthesis of a variety of
derivatives in efforts to enhance the selectivity for hypoxia imaging. The majority of these
compounds focused on functionalizing the pendant amine to enhance imaging.

Figure 1-3. Structures of CuATSM (left) and CuGTSM (right).
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As described above, the general synthetic methodology for BTSCs employs a
condensation of a thiosemicarbazide with a dione. The desired thiosemicarbazide can be
synthesized from the corresponding isothiocyanate and hydrazine.7 This synthetic route
lends itself for various amine derivatives to be incorporated into the ligand framework. The
modifications to the ligand framework are focused on tuning reduction potential or
enhancement of radioimaging. Modifications to increase uptake of the radiolabeled
compound include incorporation of the octa-peptide, octreotide, to the ligand framework.33
Modifications to tune the reduction potential of the complex include incorporation of an
alyll functionalitiy15 or a pyrollidine.39 Transamination by using 4,4-dimethyl-3thiosmeicarbazide can be employed to further modify the ligand framework by displacing
the tertiary amine with the desired primary amine. This route has been particularly useful
in the development of non-radiolabeled active imaging molecules.40 Using this route Emily
Que and co-workers32 notably incorporated a –CH2CF3 functionality off one or both
pendant amines that led to Cu complexes with an anodic shift of 70 mV per -CH2CF3 group.
Upon entering a hypoxic environment, the mono –CH2CF3 substituted CuATSM derivative
was reduced by one electron from a paramagnetic, d9 CuII to a diamagnetic, d10 CuI. The
latter compounds can be readily observed by 19F MRI due to the absence of paramagnetic
broadening that render the Cu2+ complexes unobservable. Additionally, the kinetic lability
of CuI promotes dissociation from the ligand framework adding to the image enhancement.
The CuII/I potential for the di –CH2CF3 substituted CuATSM derivative is similar to that of
CuGTSM and it is too anodic for application in hypoxia imaging. The more anodic
reduction potential of CuGTSM and related complexes makes them attractive candidates
for other applications including cancer therapeutics.

7

1.3 Cancer and BTSCs
Recently, both CuGTSM and CuATSM were evaluated for their activity against
prostate cancer cells.38 CuGTSM displayed a lower LD50 (1.5 μM) than CuATSM (7.0
μM) for the treatment of PC-3 cells. The activity of CuGTSM was attributed to an increase
of bioavailable copper, which induces apoptosis much like the related 2-keto-3-ethoxybutyraldehydebis(thiosemicarbazonato) (KTS) Cu(II) complex.41 To examine this, the cell
culture was treated with the known copper chelator tetrathiomolybdate (TTM). The
chelator affected the potency of CuGTSM, but that of CuATSM remained unchanged. This
result was confirmed by using a metal responsive element (MRE)-luciferase reporter. 42-43
Although in vitro studies provide crucial insight to potential therapies, application
in vivo is crucial for the further development of a therapy. Using the TRAMP transgenic
prostate cancer mouse model,44 both CuGTSM and CuATSM were investigated for their
viability in vivo. Weighing of the genitourinary tracts showed a 70% reduction in tumor
weight relative to the control when the mice were treated with CuGTSM. Further
evaluation using the Suttie scoring system45 showed marked improvement with the
CuGTSM treatment. It should be noted that this treatment was not without side effects.
Mice treated with CuGTSM suffered from kidney toxicity caused by copper accumulation.
Pharmokinetic experiments determined that the chelated copper does not exchange
with other metals in vivo.38 Further, ZnGTSM was examined as a potential anti-cancer
agent, but was found to be inactive in agreement with previous reports.41,46 It was
previously established that the copper ionophores clioquinol and disulfiram inhibit
proteasomal chymotrypsin-like activity.47-49 To examine if CuGTSM exhibited similar
8

effects, the expression and subcellular localization of the X-linked inhibitor of apoptosis
protein (XIAP) was monitored.49-51 Inhibition of proteasomal activity causes the
localization of XIAP to move from the cytoplasm to the nucleus. Following treatment with
CuGTSM, the XIAP was found to have been localized in the nucleus, confirming the
inhibitions of proteasomal activity by CuGTSM. This result of XIAP localization in the
nucleus was not observed following treatment with CuATSM.
The previous work done on CuGTSM by Cater et al.38 prompted the exploration for
new copper BTSCs with more anodic redox couples than CuATSM for therapeutic
purposes. Palanimuthu et al.39 focused on the incorporation of cyclic moieties into the
pendant amine. The cyclic moieties were synthesized by the condensation of 4pyrrolidinyl-3-thiosemicarbazide with benzil or butanedione or the condensation of 4methyl-4-phenylthiosemicarbazide with glyoxal. These compounds were then evaluated
for anti-cancer activity using MTT assays of the carcinogenic cell lines SiHa (cervical
cancer), MCF-7 (breast cancer), PC-3 (prostate cancer), A-2780 (ovarian cancer), and
HepG2 (hepatocellular liver cancer). The results from the MTT assays showed CuGTSC
as the most potent compound. The CuII/I couple of CuGTSC was found to be 400 mV more
anodic than CuATSM. The compound obtained from condensation of 4-pyrrolidinyl-3thiosemicarbazide with benzyl had a CuII/I couple 240 mV more anodic than CuATSM but
displayed no effect on carcinogenic cell lines other than HepG2. This result indicates that
reduction potential is not the only determinant in the anti-cancer activity.
To confirm cellular uptake and location of copper from CuGTSC and CuGSTC·HCl
in to the cancer cells, ICP-OES was employed by Palanimuthu and co-workers to show
that the copper was preferentially located in the cytoplasm rather than the nucleus after
9

treatment with CuGTSC or CuGSTC·HCl. The protonated complex, CuGSTC·HCl, is
expected to equilibrate with the buffer during evaluation to generate CuGTSC in situ. It
remains unclear as to why the observed results for both neutral and protonated differ.
Further measurement of the lipophilicity of CuGTSC and CuGSTC·HCl was conducted by
a modification of the common water and 1-octanol partition coefficient study.52
Chloroform was employed in place of octanol due to solubility issues and the conversion
factor Poctanol = (1.343 + logPchloroform)/1.126.53 The measurements revealed a correlation of
cytotoxicity with their lipophilicity, with the more lipophilic CuGTSC requiring a lower
does to achieve cytotoxicity. The compounds were then investigated to examine the
mechanism of apoptosis induction.
Several previous reports observed that CuBTSCs were capable of inhibiting DNA
synthesis.54-57 This is in contrast to the reactive oxygen species (ROS) mediated anti-cancer
activity of the mono-TSCs.54,58 Using the [3H]thymidine incorporation assay, it was found
CuGTSC (Figure 1-4) did inhibit DNA synthesis. Further, in a competition with ethidium
bromide, the binding affinities of CuGTSC and CuGSTC·HCl for DNA were determined.
These results showed that CuGSTC·HCl (i.e., charged species) displayed a higher binding
affinity for DNA than the neutral CuGTSC, indicating an electrostatic component to the
interaction. Lastly, the results from viscosity experiments pointed to intercalation as the
mode of binding.

10

Figure 1-4. CuGTSC structure.

In attempt to elucidate the mechanism related to inhibition of DNA synthesis, DNA
cleavage and topoisomerase inhibition59-62 studies were performed. Using supercoiled
pBR322 plasmid DNA and gel electrophoresis, the amount of cleaved DNA could be
measured. A Human Topo IIα kit was employed to measure the inhibition of
topoisomerase. The majority of the BTSC Cu complexes investigated did not display a
large amount of cleavage or inhibition, including CuGTSC. The protonated CuGSTC·HCl
derivative however, showed 86% cleavage and 90% inhibition, significantly higher than
CuGTSC which had values of 24% and 52%, respectively. Further the cleavage of DNA
was not mediated by ROS since the same result was found when run under in argon
atmosphere.
The interesting result of the structure activity relationship displayed by
Palanimuthu was advanced by Palma and co-workers.63 Incorporating cyclic amines as the
pendant amine of the BTSC resulted in reduction potential closer to CuATSM than
CuGTSM. While this modification led to enhanced cytotoxicity, there was decreased
selectivity for carcinogenic versus healthy cells. The observed increase in cytotoxicity was
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attributed to the increased lipophilicity conferred by the cyclic amine increasing cellular
uptake relative to CuATSM. Although cellular uptake was increased, the efflux rate of the
compound with cyclic amines remained unchanged compared to CuATSM.64 It should be
noted that the presence of a pendant secondary amine may lead to efflux via multidrug
resistant protein one (MDR-1) for BTSC complexes.65
For anti-cancer activity with BTSCs the metal employed has generally been copper.
Recently, a series of cobalt(III) containing BTSCs11 was evaluated for their anti-cancer
properties. As observed with Cu, the easier to reduce species were found to be the most
potent. However, this class of compounds displayed relatively poor activity. Interestingly,
when copper was scrubbed from culture medium with tetrathiomolybdate,66-68 the
anticancer activity was further diminished, indicating a copper dependence. Further studies
have not been performed to elucidate if this result is an effect of metal exchange or other
Cu-mediated processes.
1.4 Hydrogen Evolution and BTSCs
Whereas cancer applications of BTSCs focus primarily on modulation of the
reduction potential, HER catalysts require an understanding of ligand basicity. The US
energy economy is largely been based on non-renewable resources, Figure 1-5.69 A major
drawback of renewable energy sources such as solar and wind is the need to store energy
for peak usage. The use of H2 as an energy carrier is considered green as the combustion
of H2 produces water rather than greenhouse gasses as a product. However, for a whole
process to be considered green, the production of H2 also needs to be ecologically friendly.
The two industrially employed techniques of H2 production are steam methane reformation
and coal gasification, both of which generate CO2 as a byproduct. The cleanest way to
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produce hydrogen is by splitting water. Crucially, the reaction is non-spontaneous and
requires a thermodynamic potential of 1.23 V. However, any system employed will have
to supply additional energy to overcome the overpotential. Overpotential results from an
activation barrier due to electron transfer barriers and diffusion effects. The ideal catalyst
will operate at a minimal overpotential and be capable of economic scale up.

Figure 1-5. Distribution of energy consumption in the US.69

Recently Haddad et al. evaluated the H2ATSM ligand and ZnATSM as
homogeneous HER catalysts.10 This was the first evaluation of BTSCs as possible HER
catalysts and metal-free HER catalysis. The Zn complex was a viable HER catalysts in
both acetonitrile and methanol, whereas the ligand was active only in methanol. The cyclic
voltammogram of H2ATSM displayed one irreversible reduction at –2.1 V vs Fc+/Fc in the
absence of acid. Titration of acetic acid to a 3 mM ligand solution lead to an increase of
current at -2.1 V until the acid reached 9.8 mM, at which the current plateaued. The
turnover frequency (TOF) from the ligand to produce hydrogen was 1320 s-1 with an
overpotential of 1.43 V.
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The Zn complex performed better compared to the ligand in methanol. It should be
noted that the Zn complex displayed no reduction events in the absence of acid in the cyclic
voltammogram. Upon addition of acid, a catalytic peak was observed at –1.7 V, implying
the first step of HER with ZnATSM is protonation. Acetic acid was added up to 12.0 mM,
upon which the increase in current plateaued. Under these conditions, the TOF was found
to be 1170 s-1, slightly lower than the free ligand. However, the overpotential of the Zn
derivative in methanol was 0.756 V, which is 0.674 V lower than with the ligand alone.
With an identical environment, a bulk electrolysis over the course of 2.5 hours gave a
turnover number (TON) of 37 with a Faradaic efficiency of 85%. Interestingly in
acetonitrile, the acid plateau occurred at 23 mM, giving an order of magnitude larger TOF
of 11,700 s-1 but with a larger overpotential of 1.074 V. This large difference could
potentially arise from a change in the properties of the solvents after addition of acid such
as the dielectric constant. No studies were performed to measure the change of the physical
properties of the solvents. The catalytic event was found to be at –2.3 V which is close to
the free ligand reduction even without acid.
The mechanistic studies revealed that the reaction is first order with respect to both
ZnATSM and acetic acid.70 Kinetic isotope effect (KIE) experiments71-73 in acetonitrile,
using deuterated acetic acid gave a value of 1.2, which is unique from those previously
reported for HER electrocatalysts, insinuating an unprecedented mechanism of action.
Combining simulations and density functional theory (DFT) calculations, two plausible
mechanisms were determined. It is crucial to note that both pathways involve ligand
centered radical coupling, require protonation as the first step, and require the cooperation
of two complexes, Scheme 1-1.
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Scheme 1-1. ZnATSM possible HER mechanisms.

In an effort to improve the performance of the ATSM framework as a HER catalyst,
Haddad et al. evalutaed CuATSM.34 The hypothesis being that the metal center could assist
in the ligand reactivity. Prior to any acid additions a reversible reduction was observed at
-1.20 V vs Fc+/Fc0 in acetonitrile, which is assigned to the CuII/I couple. Addition of acid
led to an anodic shift of this event to –0.95 V, indicative of protonation prior to catalysis.
This was later confirmed via spectrophotometric titrations and simulations. Addition of
acid also led to a new cathodic peak at -1.70 V. Interestingly, at lower acid concentrations,
the mechanism is second order with respect to acid. However, as concentrations increase,
it becomes independent of acid concentration at 0.269 M. This change in acid dependency
is indicative of a pre-equilibrium step prior to H2 release. The TOF for this system was
found to be 10,000 s-1, with an overpotential 0.8 V, which is 0.3 V lower than ZnATSM.10
Identical studies were performed in DMF, however the catalytic activity was significantly
diminished as compared to studies in acetonitrile. It is hypothesized that this is due to the
strong hydrogen bonding nature of DMF. KIE experiments gave a value of 7.54 which is
consistent with that observed for a ligand centered rhenium thiolate HER catalyst.74
Further, it was revealed that one proton was involved in the rate determining step. From

15

the combination of experimental results, digital simulations of cyclic voltammogram (CV)
data, and DFT calculations a mechanism was proposed, Scheme 1-2. Each step of the
mechanism was confirmed by DFT to be the lowest energy state. While both Zn and
CuATSM undergo a CECE mechanism, chemical protonation (C) followed by reduction
(E), the copper proceeds through a monomeric pathway in contrast with the zinc. Another
difference between these two systems was the development of a film on the working
electrode following bulk electrolysis for the copper derivative but not for the zinc. Thus, it
is impossible to rule out any heterogeneous effects of HER catalysis for the copper
complex.

Scheme 1-2. Mechanism for H2 evolution from CuATSM.

With a wide variety of ligands available, Straistari and co-workers synthesized and
studied the HER catalysis of a NiATSM derivative.35 This particular derivative replaced
the methyl off the pendant amine with para-anisole, Figure 1-6. This was then used to
chelate nickel giving a complex with reduction events at -1.57 and -2.10 V in DMF. With
the addition of trifluoroacetic acid, a new reduction event occurred at -1.23 V. This was
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attributed to HER catalysis and reached acid saturation at 100 mM. Using foot-of-the-wave
analysis, a TOF was calculate to be 3080 s-1.

Figure 1-6. Structure of NiATSM para-anisole.

Bulk electrolysis at -1.73 V gave a TON of 21 and a Faradaic efficiency of 80%.
Interestingly, control experiments did not reveal any formation of a film or nanoparticles
during the course of the bulk electrolysis. Further mechanistic studies were carried out
using DFT computations. The first reduction was assigned as ligand centered and the
subsequent reduction was found to be metal centered. When a proton is added after the first
reduction, the site of protonation was found to be the imino nitrogen of the ligand
framework. Reduction after this protonation remained on the nickel, as previously
established in the absence of acid. A NiIII-H hydride is produced after the second
protonation event prior to H2 release. This novel mechanism was the first to use the metal
center directly to evolve H2 for the BTSC class of compounds. The overpotential of this
novel NiBTSC system was lower than the previously reported ATSM derivatives studied
by Haddad et al.10,34
The results from Straistari et al.35 led Jain et al. to evaluate the electrocatalytic
behavior of NiATSM.75 The cyclic voltammograms displayed two reversible reductions at
-1.83 and -2.45 vs Fc+/Fc in acetonitrile. These values for NiATSM are cathodically shifted
to those of the para-anisole derivative reported by Straistari et al.35 Upon addition of acetic
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acid, a catalytic peak was observed at -2.35 V and reached plateau after the addition of 12.6
mM. This corresponded to a TOF of 4,200 s-1, an overpotential of 0.53 and a TON of 48
after 4 hours. Trifluoroacetic acid was also used as an acid, while there was an anodic shift
in the catalytic peak to -2.26 V, the overall performance diminished. The corresponding
TOF, overpotential, and TON were 1,300 s-1, 0.67 V and 24. The same trend was observed
when DMF was used as a solvent. Overall, the performance of the catalyst in DMF was
lower. As previously mentioned this is caused by the hydrogen bonding of DMF.
Mechanistic studies were performed on NiATSM, including concentration
dependence studies, which revealed the reaction is first order with respect to the catalyst.
There was no evidence of the formation of a film or nanoparticles. Spectrophotometric
titrations displayed no protonation of the complex without prior reduction, in agreement
with previous reports. The experimentally determined KIE value was inverse 1, which is
consistent with the formation of a metal hydride. Combining these experimental results
with DFT computations a mechanism was postulated. A ligand centered reduction occurs
prior to protonation at the hydrazine nitrogen. The second reduction occurs on the metal
center resulting in a metal hydride. This hydride intermediate is then capable of reacting
with a proton in solution to evolve H2. Overall, the mechanism is ECEC. The mechanism
is slightly different from that proposed by Straistari et al. for the para-anisole nickel
complex (Figure1-6) as the first protonation occurs on the hydrazino nitrogen for NiATSM,
whereas it is reported to occur on the imino nitrogen by Straistari et al.35
Straistari and co-workers continued to examine the effect of the chelated metal on
overall performance of the catalyst.12 The same para-anisole BSTC ligand was used to
prepare the palladium complex. This is the first example of a later row transition metal
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being employed with the BTSC ligand framework as a HER catalyst, however still
remaining in the same family as nickel. Two reduction events are observed in the cyclic
voltammogram in DMF, at potentials similar to the nickel derivative at -1.55 and -2.07 V.
Following the reported methods for the nickel complex the centers of the reduction were
determined using DFT. The reductive events were again found to first occur on the ligand
and then on the metal, like the previous nickel systems.35,76 These results were further
corroborated by calculation of the reduction potentials.
The palladium system was then evaluated for its viability as a HER catalyst.
Trifluoroacetic acid was added until saturation occurred at 100 mM. As the previously
described nickel system is proposed to operate via ECEC, so is the palladium.35,76 DFT
calculations were carried out to confirm this, along with spectrophotometric titrations that
showed that the complex did not protonate upon the addition of trifluoroacetic acid without
first undergoing a reduction. Interestingly, the first protonation event, while still ligand
centered was found to occur on the hydrazino nitrogen as in CuATSM. The full HER
mechanism is much like that of CuATSM involving the radical coupling of two ligand
centered hydrogens, Scheme 1-2.
A drawback of homogenous catalysis is the lack of long term stability and relatively
large overpotentials. Heterogeneous catalysts generally offer a longer lifetime, but current
ones are more expensive as they generally employ precious metals. The current standard
for heterogeneous HER catalysis is a platinum electrode which operates at nearly no
overpotential. While a multitude of work has been done on developing more cost efficient
heterogeneous catalysts, there has yet to be any implementation of BTSCs on an electrode
surface. As described earlier, CuATSM even under homogeneous conditions generated a
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film on the electrode surface. Zhang et al. expanded upon this by drop-casting various
BTSCs on a glassy carbon surface.77
The ligand frameworks that were examined were ATSM and ATSP (Figure 1-7) as
well as their copper and zinc chelates. Using scanning electron microscopy (SEM), all
catalysts were evaluated before and after reductive cycling. It was apparent in all cases that
after reductive cycling the film from the deposited catalyst was roughened by the evolution
of hydrogen. In the cases of the ligand this meant a uniform film became reorganized and
in the metal complexes, microcrystals became more amorphous.

Figure 1-7. Structure of CuATSP.

To confirm stability of the film after deposition on the working electrode, XPS was
employed. For both frameworks, the ligand and copper complex were found to remain
intact on the electrode surface. The zinc derivatives however were found to demetallate
during the reductive cycling; the ligand remained intact though. This was also confirmed
by UV-visible spectroscopy, in which after reductive cycling the zinc compounds
electronic spectra were identical to that of the free ligand indicating they were no longer
zinc chelates.
20

It should be noted that various loading amounts were required to achieve optimum
performance for each system. Overall the best system was found to be copper derivatives,
with an overpotential of 0.774 V and 0.745 V for CuATSM and CuATSP, respectively.
While this is not a marked improvement from the homogeneous system of the 0.8 V
overpotential for CuATSM,34 the immobilization of these compounds on the electrode
surface displayed longevity of over 25 hours. One technique that has yet to be fully
exploited is the generation of carbon paste electrodes with BTSCs. Zhang et al. showed
that the synthesis of such an electrode with CuATSM led to a dramatic decrease in the
overpotential to 0.531 V.
1.5 Summary
Overall BTSCs represent a versatile class of ligands suitable for numerous
applications. The synthetic methodology lends itself to be varied in a multitude of locations
to generate an extensive library of compounds. This modular synthesis dovetails with the
need to fine tune the redox activity for the diverse applications in which these systems are
employed. Applications that exploit the redox activity and ease of synthesis include
hydrogen evolution catalysis, radioimaging, and therapeutics. In this dissertation, the
library of BTSCs and structurally related derivatives, including a hybrid system, are
expanded and explored for their use in heterogeneous HER and anti-cancer activity.
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CHAPTER II
EXPERIMENTAL
2.1 Physical Methods
Elemental analyses were performed by Midwest Microlab (Indianapolis, IN). The
electronic spectra were measured in quartz cuvettes (1 cm pathlength) using an Agilent
8453 diode array spectrometer. Mass spectrometry (ESI-MS, positive mode) was
performed by the Regenerative Medicine Research Center at the West China Hospital,
Sichuan University, Chengdu, China or the Laboratory for Biological Mass Spectrometry
at Texas A&M University, or MALDI-TOF at the University of Louisville. X-band
electronic paramagnetic resonance (EPR) spectra were collected on powder samples at
room temperature using a Bruker EMX (Bruker, Billerica, MA) spectrometer and
simulated using EasySpin (MATLAB, version 5.2.23).78 The infrared spectra were
recorded on a Thermo Nicolet 360 FT-IR spectrophotometer with ATR attachment
(Thermo Fisher, Waltham, MA). NMR spectra were obtained on Varian 400 MHz
spectrometer at 25 °C. X-ray crystallographic studies were performed by Dr. Mark
Mashuta at the Department of Chemistry, University of Louisville on an Agilent
Technologies/Oxford Diffraction Gemini CCD diffractometer (Agilent Technologies,
Santa Clara, CA) .
2.2 Electrochemical Measurements
Homogeneous electrochemical data were collected using a Gamry Interface 1000E
Potentiostat/Galvanostat/ZRA to perform all cyclic voltammetry (CV) experiments using
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glassy carbon working electrode (diameter = 6.5 mm, surface area = 0.07 cm2), a
platinum wire counter electrode, and Ag/AgCl reference electrode, with the exception of
DCM which employed a silver wire as the reference electrode. All reported potentials are
referenced versus ferrocenium/ferrocene (Fc+/Fc0). The working electrode was polished
with alumina slurry prior to use. Both the working and counter electrode were washed with
water, ethanol, acetone and sonication in working solvent (15 min) prior to use. All CV
experiments were performed under an inert atmosphere (either N2 or Ar) in a three-neck
electrochemical cell that was washed and dried overnight prior to use.
For CV measurements a working solvent was selected and a 0.1M of
tetrabutylammonium hexafluorophospate was added. This was then degassed for 15 min
by sparging the working solvent with either argon or nitrogen. The solvent was scanned
over the full window to ensure no contaminants were present. The compound of interest
was then added and the system was then purged with argon or nitrogen for another 15
minutes to ensure no oxygen was present. The CVs of the complex could then be recorded.
After completion of the CV experiment, a small quantity of ferrocene was added to act as
an internal standard. For HER catalysis evaluation, glacial acetic acid was added, after
which the solution was sparged with either nitrogen or argon to ensure a consistent
concentration of acid. The system was allowed to rest after bubbling to ensure the reaction
was diffusion controlled.
Heterogeneous evaluation of the activities of 2, 28, and 29 for HER was carried out
in a three-electrode glass electrochemical cell (RDE/RRDE cell without water jacket, Pine
Research, Durham, NC) with 0.5 M H2SO4 (VWR, ACS grade) in twice-deionized
millipore water (18.2 Ωcm). A graphite rod (Pine Research), in a protective fritted glass
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tube (Pine Research), was used as the counter electrode. Ag/AgCl (CH Instruments, Bee
Cave, TX) was used as the reference electrode. Measured potentials were calibrated vs.
RHE after experiments were conducted (to prevent platinum contamination) by measuring
the potential difference between a pristine platinum electrode (Standard Platinum Counter
Electrode, Pine Research) and the reference electrode in H2-saturated H2SO4. High-purity
H2 and N2 were used throughout these experiments (Welders Supply, Louisville, KY).
A Metrohm Autolab PGSTAT302N potentiostat/galvanostat, operating in
potentiostat mode, was used to obtain polarization and frequency response analysis (FRA)
data. Reductive cycling to activate the catalyst and evaluate its stability was carried out
between 0 V and –0.8 V vs. RHE at 50 mV/sec. Linear sweep voltammetry was carried out
intermittently throughout the cycling process, from 0 V to –0.8 V vs. RHE at 2 mV/sec, to
evaluate the activity of the catalyst, at a relatively high resolution, after various amounts of
usage at reductive potentials. FRA data was collected with an applied DC bias of –0.3 V
vs. RHE, starting at 100 kHz and finishing at 0.02 Hz, with 5 mVRMS amplitude. The
working electrode was rotated at 800 RPM throughout electrochemical characterization to
assist the diffusion of H2 gas away from the catalyst surface. Measured values were iRcompensated by multiplying the measured current at each point by the real component of
resistance measured at 100 kHz and then subtracting these values from the corresponding
applied potentials.
2.3 Synthetic Procedures
All reagents and solvents were purchased from commercial sources and used as
received unless otherwise indicated. Reactions were conducted open to air and under
ambient conditions unless otherwise noted. Solvents ethanol and methanol were grades
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absolute and 99.8%, respectively. Xanthates,79 hydrazinecarbothioic acid O-alkyl esters80,
mono-keto-thiosemicarbazones,18,81 H2ATSM, H2ATSDM, H2ATSM-F6, 1, 2, and 3 were
synthesized according to literature methods.8,32
N,N′-bis(methylthiocarbamate)butane-2,3-diimine (4). The hydrazinecarbothioic acid
O-methyl ester (3.2 g, 30 mmol) was dissolved in ethanol (50 mL). To this solution 2,3butanedione (1.3 mL, 15 mmol) was added by syringe with stirring. A catalytic amount (5
drops) of concentrated sulfuric acid was added resulting in a white precipitate. The
suspension was stirred for 16 h. The white precipitate was isolated by filtration and washed
with ethanol and ether. Yield = 3.6 g (93%). 1H NMR, (C2D6SO, 400 MHz) δ 2.11 (s, 6H)
4.03 (s, 6H) 11.46 (s, 1H) 11.77 (s, 1H). 13C {1H} NMR, (CDCl3, 100 MHz) δ 12.3, 58.5,
117.8, 188.0. IR, cm-1: 3240 (w) and 1503 (m) (NH) 1419 (m) (CH) 1341 (m) and 1222 (s)
(CN) 1137 (s) (CO) 1060 (s) (CS).
N,N′-bis(ethylthiocarbamate)butane-2,3-diimine (5). Compound 5 was prepared using
the same protocol as for 4. Addition of 2,3-butanedione (2.3 mL, 27 mmol) to
hydrazinecarbothioic acid O-ethyl ester (6.4 g, 53 mmol) in ethanol (50 mL) yielded 2 as
a white solid. Yield = 7.74 g (98%). 1H NMR, (C3D7NO, 400 MHz) δ 1.51 (br, 6H) 2.46
(br, 4H) 4.74 (s, 6H) 11.51 (s, 1H) 11.92 (s, 1H). IR, cm-1: 3241 (w) and 1498 (s) (NH)
1403 (m) (CH) 1317 (m) and 1211 (s) (CN) 1135 (m) (CO) 1049 (m) (CS).
N,N′-bis(n-propylthiocarbamate)butane-2,3-diimine (6). Compound 6 was prepared as
described for 4 from hydrazinecarbothioic acid O-propyl ester (2.1 g, 15 mmol) and 2,3butanedione (0.66 mL, 7.5 mmol) in ethanol (50 mL). Yield = 0.95 g (40%). 1H NMR,
(CDCl3, 400 MHz) δ 0.99 (t, 6H, J=7.28 Hz) 1.84 (quint, 4H, J = 6.24 Hz) 2.13 (s, 6H)
4.55 (t, 4H, J = 6.22 Hz) 9.15 (s, 2H).
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C{1H} NMR, (CDCl3, 100 MHz) δ 9.78, 10.3,
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21.9, 29.7, 187.6. IR, cm-1: 3234 (w) and 1497(s) (NH) 1402 (m) (CH) 1334 (m) and 1207
(s) (CN) 1135 (s) (CO) 1052 (s) (CS).
N,N′-bis(isopropylthiocarbamate)butane-2,3-diimine (7). Compound 7 was prepared as
described for 4 from hydrazinecarbothioic acid O-isopropyl ester (5.1 g, 38 mmol) and 2,3butanedione (1.7 mL, 19 mmol) in ethanol (50 mL). Yield = 1.4 g (23%). 1H NMR, (CDCl3,
400 MHz) δ 1.41 (br, 12H) 2.12 (s, 6H) 5.63 (br, 2H) 9.10 (s, 2H). 13C{1H} NMR, (CDCl3,
100 MHz) δ 10.3, 21.9. IR, cm-1: 3234 (w) and 1497(s) (NH) 1402 (m) (CH) 1334 (m) and
1207 (s) (CN) 1135 (s) (CO) 1052 (s) (CS).
N,N′-bis(octylthiocarbamate)butane-2,3-diimine (8). Compound 8 was prepared as
described for 4 from hydrazinecarbothioic acid O-octyl ester (2.72 g, 13 mmol) and 2,3butanedione (0.58 mL, 6.7 mmol) in ethanol (50 mL,). Yield = 1.77 g (58%). 1H NMR,
(CDCl3, 400 MHz) δ 0.87 (br, 6H) 1.28 (m, 16H) 1.43 (br, 4H) 1.81 (br, 4H) 2.13 (s, 6H)
4.59 (br, 4H) 9.12 (s, 2H). 13C{1H} NMR, (CDCl3, 100 MHz) δ 14.1, 22.6, 25.8, 28.4, 29.1,
31.7. IR, cm-1: 3230 (w) and 1497 (vs) (NH) 2950-2850 (m) and 1404 (s) (CH) 1326 (s)
and 1206 (vs) (CN) 1136 (s) (CO) 1056 (s) (CS).
N,N′-bis(ethylthiocarbamate)hexane-3,4-diimine (9). Compound 9 was prepared as
described for 4 from hydrazinecarbothioic acid O-ethyl ester (1.53 g, 13 mmol) and 3,4hexanedione (0.77 mL, 6.5 mmol) in ethanol (50 mL). Yield = 1.2 g (60%). 1H NMR,
(CDCl3, 400 MHz) δ 1.08 (br, 6H) 1.41 (br, 6H) 2.63 (br, 4H) 4.63 (br, 4H) 9.23 (br, 2H).
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C{1H} NMR, (CDCl3, 100 MHz) δ 10.49, 14.02, 17.01, 68.87, 152.27, 187.47. IR, cm-1:

3235 (w) and 1498 (m) (NH) 1433 (w) (CH) 1314 (m) and 1206 (s) (CN) 1152 (m) (CO)
1059 (s) (CS).
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Cu(MTCB) (10). Compound 4 (0.273 g, 1.29 mmol) was suspended in methanol (25 mL,
100%). To this suspension copper(II) acetate monohydrate (0.285 g, 1.49 mmol) was added
with stirring giving a red-brown precipitate. The suspension was refluxed with stirring for
4 h and then allowed to cool to room temperature. The formed solid was filtered, washed
with methanol then ether and air dried. Yield = 0.216 g (52%). X-ray quality crystals were
obtained by slow evaporation of a DCM solution of 10 layered with ethanol. IR, cm-1 :
1471 (s) and 1398 (m) (CH) 1241 (vs) and 1218 (vs) (CN) 1091 (w) (CO) 948 (w) (CS)
848 (w) (CuS) 771 (w) (CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 246
(16,000), 290 (20,000), 486 (2,680). EPR g = 2.061. Elemental analysis calc. for
C8H12S2O2N4Cu: C, 29.67, H, 3.73, N, 17.30, O, 9.88, S, 19.80. Found: C, 28.49, H, 3.58,
N, 15.97, O, 8.54, S, 17.87. Mass spectrum calc. for C8H12S2O2N4Cu: 322.9698. Found:
322.9775.
Cu(ETCB) (11). Compound 11 was prepared using the method described for 10 from 5
(0.309 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol
(25 mL). Complex 11 was isolated as a red-brown solid. Yield = 0.237 g (52%). X-ray
quality crystals were obtained by using the technique described for 10. IR, cm-1: 1413 (s)
(CH) 1216 (s) (CN) 1020 (m) (CO) 867 (w) (CS) 792 (w) (CuS) 673 (w) (CuN). UVVisible spectrum in DCM, nm, (M-1 cm-1): 248 (16,300), 290 (22,700), 485 (2920). EPR
g|| = 2.131 and g = 2.036. Elemental analysis calc. for C10H16S2O2N4Cu: C, 34.13, H, 4.58,
N, 15.92, O, 9.09, S, 18.22. Found: C, 34.08, H, 4.40, N, 15.46, O, 9.18, S, 18.22. Mass
spectrum calc. for C10H16S2O2N4Cu: 351.0011. Found: 351.0086.
Cu(PTCB) (12). Compound 12 was prepared using the method described for 10 from 6
(0.408 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol
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(25 mL). Complex 12 was isolated as a red-brown solid. Yield = 0.322 g (68%). X-ray
quality crystals were obtained by using the technique described for 10. IR, cm-1: 1467 (w)
and 1423 (s) (CH) 1236 (s) (CN) 1093 (w) (CO) 956 (m) (CS) 844 (w) (CuS) 632 (w)
(CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 248 (16,600), 291 (23,800), 484
(2,930). EPR g|| = 2.127 and g = 2.034. Elemental analysis calc. for C12H20S2O2N4Cu: C,
37.93, H, 5.31, N, 14.74, O, 8.42, S, 16.88. Found: C, 37.99, H, 5.10, N, 14.67, O, 8.32, S,
16.75 Mass spectrum calc. for C12H20S2O2N4Cu: 379.0324. Found: 379.0417.
Cu(iPTCB) (13). Compound 13 was prepared using the method described for 10 from 7
(0.408 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol
(25 mL). Complex 13 was isolated as a red-brown solid. Yield = 0.291 g (60%). X-ray
quality crystals were obtained by using the technique described for 10. IR, cm-1: 1427 (s)
(CH) 1213 (vs) (CN) 1103 (vs) (CO) 910 (m) (CS) 831 (w) (CuS) 671 (w) (CuN).
Elemental analysis calc. for C12H20S2O2N4Cu: C, 37.93, H, 5.31, N, 14.74, O, 8.42, S,
16.88. Found: C, 37.38, H, 5.16, N, 14.39, O, 8.61, S, 17.10. UV-Visible spectrum in DCM,
nm, (M-1 cm-1): 248 (16,500), 292 (23,600), 484 (3,210). EPR g|| = 2.089 and g = 2.042.
Mass spectrum calc. for C12H20S2O2N4Cu: 379.0324. Found: 379.0401.
Cu(OTCB) (14). Compound 14 was prepared using the method described for 10 from 8
(0.589 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol
(25 mL). Complex 14 was isolated as a red-brown solid. Yield = 0.554 g (83%). X-ray
quality crystals were obtained by using the technique described for 10. IR, cm-1: 2960-2852
(m) and 1423 (s) (CH) 1238 (vs) (CN) 1079 (w) (CO) 946 (m) (CS) 846 (m) (CuS) 676
(w) (CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 248 (15,900), 291 (23,600), 485
(3,100). EPR g|| = 2.130 and g = 2.034. Elemental analysis calc. for C22H40S2O2N4Cu: C,
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50.79, H, 7.75, N, 10.77, O, 6.15, S, 12.33. Found: C, 50.49, H, 7.57, N, 10.65, O, 6.34, S,
12.59. Mass spectrum calc. for C22H40S2O2N4Cu: 519.1889. Found: 519.1986.
Cu(ETCH) (15). Compound 15 was prepared using the method described for 10 from 9
(0.408, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol
(25 mL). Complex 15 was isolated as a red-brown solid. Yield = 0.401 g (82%). X-ray
quality crystals were obtained by using the technique described for 7. IR, cm-1: 1417 (s)
(CH) 1221 (s) (CN) 1016 (s) (CO) 974 (w) (CS) 874 (m) (CuS) 630 (m) (CuN). UV-Visible
spectrum in DCM, nm, (M-1 cm-1): 249 (18,300), 292 (25,000), 485 (3,340). EPR g|| = 2.124
and g = 2.031. Elemental analysis calc. for C12H20S2O2N4Cu: C, 37.93, H, 5.31, N, 14.74,
O, 8.42, S, 16.88. Found: C, 37.71, H, 4.96, N, 14.43, O, 8.33, S, 16.95. Mass spectrum
calc. for C12H20S2O2N4Cu: 379.0324. Found: 379.0315.
H2MEB (16). Diacetyl-2-(4-N-methyl-3-thiosemicarbazone) (0.894 g, 6.3 mmol) was
suspended in ethanol (25 mL), and hydrazinecarbothioic acid O-ethyl ester (0.760 g, 6.3
mmol) was added. A catalytic amount (6 drops) of concentrated sulfuric acid was added
resulting in a white precipitate. The solid was isolated by filtration and washed with water
then ethanol. Yield = 1.32 g (76%). 1H NMR, (C2D6SO, 400 MHz), δ 1.28 (br, 3H), 2.11
and 2.17 (br, 6H), 3.00 (s, 3H), 8.35 (s, 1H), 10.21 (s, 1H) 11.31 and 11.62 (s, 1H).

13

C

NMR, (C2D6SO, 100 MHz) δ 11.8, 12.5, 31.7, 66.3, 67.5, 147.9, 152.5, 179.0, 187.0. IR,
cm-1: 3382, 3253, 1541, 1494 (NH), 2991 and 1411 (CH), 1304 and 1217 (CN), 1130 (CO),
1053 (CS). Elemental analysis calc. for C9H17S2ON5: C, 39.25, H, 6.22, N, 25.43. Found:
C, 39.12, H, 6.16, N, 25.54.
H2MPB (17). Compound 17 was prepared using the method for 16. Addition of
hydrazinecarbothioic acid O-propyl ester (0.1.45 g, 11 mmol) to diacetyl-2-(4-N-methyl29

3-thiosemicarbazone) (1.58 g, 11 mmol) in ethanol (25 mL) yielding a white solid. Yield
= 1.32 g (75%). 1H NMR, (C2D6SO, 400 MHz), δ 0.94 (br, 3H) 1.70 (br, 2H), 2.11 and
2.19 (s/br, 6H) 3.00 (s, 3H) 4.41 (br, 2H) 8.43 (s, 1H) 10.25 (s, 1H) 11.35 and 11.63 (s,
1H). 13C NMR, (C2D6SO, 100 MHz), δ 10.8, 22.0, 31.7, 179.0. IR, cm-1: 3382, 3231, 1540,
1497 (NH), 2968 and 1411 (CH), 1303 and 1211 (CN), 1132 (CO), 1068 (CS). Elemental
analysis calc. for C10H19S2ON5: C, 41.50, H, 6.62, N, 24.20. Found: C, 41.31, H, 6.46, N,
24.02.
H2MEP (18). Compound 18 was prepared from using the method described for 16.
Addition of hydrazinecarbothioic acid O-ethyl ester (0.43 g, 3.6 mmol) to 1-phenyl-2propanone-1-(4-N-methyl-3-thiosemicarbazone) (0.840 g, 3.6 mmol) in ethanol (25 mL)
yielding a white solid. Yield = 0.871 g (72%). IR, cm-1: 3336, 3223, 1476, 1542 (NH),
2937 and 1417 (CH), 1301 and 1219 (CN), 1195 (CO), 1081 (CS). Elemental analysis calc.
for C14H19S2ON5: C, 49.83, H, 5.67, N, 20.75. Found: C, 49.14, H, 5.60, N, 20.18.
Cu(MEB) (19). Compound 16 (0.354 g, 1.29 mmol) was suspended in methanol (25 mL,
100%). To this suspension copper(II) acetate monohydrate (0.285 g, 1.49 mmol) was added
with stirring giving a red-brown precipitate. The suspension was refluxed with stirring for
4 h and then cooled to room temperature. The solid was then filtered and washed with
methanol. Yield = 0.220 g (51%). IR, cm-1: 3305 and 1561 (NH), 2937 and 1439 (CH),
1382 and 1217 (CN), 1132 (CO), 1025 (CS), 846 (CuS) 782 (CuN). UV-Visible spectrum
in DCM, nm, (M-1 cm-1): 248 (16,000), 309 (20,000), shoulder around 346 (11,000), 473
(5,100). EPR g = 2.061. Elemental analysis calc. for C9H15S2ON5Cu: C, 32.08, H, 4.49,
N, 20.79. Found: C, 31.53, H, 4.34, N, 20.26 Mass spectrum calc. for C9H15S2ON5Cu:
336.00141. Found: 337.0080.
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Cu(MPB) (20). Compound 20 was prepared using the same method as described for 19
from 17 (0.373 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in
methanol (25 mL). Compound 20 was isolated as a red-brown solid. Yield = 0.200 g (44%).
IR, cm-1: 3329 and 1562 (NH), 2972 and 1465 (CH), 1382 and 1219 (CN), 1019 (CO), 974
(CS), 872 (CuS), 758 (CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 249 (13,000),
310 (17,000), shoulder around 346 (8,700), 477 (4,300). EPR g|| = 2.116 and g = 2.030.
Elemental analysis calc. for C10H17S2ON5Cu: C, 34.22, H, 4.88, N, 19.96. Found: C, 34.17,
H, 4.83, N, 20.01. Mass spectrum calc. for C10H17S2ON5Cu: 350.01706. Found: 351.0239.
Cu(MEP) (21). Compound 21 was prepared using the same method as described for 19
from 18 (0.435 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in
methanol (25 mL). Compound 21 was isolated as a red-brown solid. Yield = 0.146 g (29%).
IR cm-1. 3324 and 1538 (NH), 2973 and 1428 (CH), 1382 and 1219 (CN), 1019 (CO), 974
(CS), 872 (CuS) 758 (CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): Shoulder
around 263 (16,000), 309 (20,000), shoulder around 357 (13,000), 485 (5,500). EPR g|| =
2.135 and g = 2.032. Elemental analysis calc. for C14H17S2ON5Cu: C, 42.14, H, 4.29, N,
17.55. Found: C, 41.84, H, 4.22, N, 17.53. Mass spectrum calc. for C14H17S2ON5Cu:
398.01706. Found: 339.0238.
Ni(MEB) (22). Compound 16 (0.354 g, 1.29 mmol) was suspended in methanol (25 mL).
To this suspension nickel(II) acetate tetrahydrate (0.353 g, 1.49 mmol) was added with
stirring giving a dark brown precipitate. The suspension was refluxed for 4 h and then
cooled to room temperature prior to being placed in a freezer overnight. The formed solid
was filtered cold then washed with methanol. Yield = 0.326 g (76%). 1H NMR, (C2D6SO,
400 MHz), δ 1.21 (t, 3H) 2.00 (s, 6H) 2.81(s, 3H) 4.20 (br, 2H) 8.03 (s, 1H). IR, cm-1: 3414
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and 1553 (NH), 2937 and 1402 (CH), 1382 and 1216 (CN), 1080 (CO), 1014 (CS), 872
(NiS), 782 (NiN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 255 (38,000), shoulder
around 326 (6,400), 389 (12,000). Elemental analysis calc. for C9H15S2ON5Ni: C, 32.55,
H, 4.55, N, 21.09. Found: C, 32.09, H, 4.44, N, 20.54. Mass spectrum calc. for
C9H15S2ON5Ni: 331.00716. Found: 331.0062 and 332.0140.
Ni(MPB) (23). Compound 23 was prepared using the method described for 22 from 17
(0.373 g, 1.29 mmol) and nickel(II) acetate tetrahydrate (0.353 g, 1.49 mmol) in methanol
(25 mL). Compound 23 was isolated as a dark brown solid. Yield = 0.250 g (56%). 1H
NMR, (C2D6SO, 400 MHz) δ 0.87 (t, 3H) 1.59 (br, 2H) 2.01 (br, 6H) 2.81 (s, 3H) 4.12 (br,
2H) 8.02 (s, 1H). IR, cm-1: 3341 and 1562 (NH), 29333 and 1493 (CH), 1307 and 1225
(CN), 1084 (CO), 1042 (CS), 855 (NiS) 735 (NiN). UV-Visible spectrum in DCM, nm,
(M-1 cm-1): 255 (32,000), shoulder around 330 (4,500), 388 (11,000). Elemental analysis
calc. for C10H17S2ON5Ni: C, 34.70, H, 4.95, N, 20.24. Found: C, 34.49, H, 4.86, N, 19.92.
Mass spectrum calc. for C10H17S2ON5Ni: 345.02281. Found: 345.0128 and 346.0296.
Ni(MEP) (24). Compound 24 was prepared using the method described for 22 from 18
(0.435 g, 1.29 mmol) and nickel(II) acetate tetrahydrate (0.353 g, 1.49 mmol) in methanol
(25 mL). Compound 24 was isolated as a dark brown solid. Yield = 0.332 g (65%). 1H
NMR, (C2D6SO, 400 MHz) δ 1.12 (t, 3H) 1.80 (s, 3H) 2.85 (s, 3H) 7.46 (br, 5H) 8.19 (s,
1H). IR, cm-1: 3408, 3256, and 1544 (NH), 2975 and 1500 (CH), 1332 and 1226 (CN),
1016 (CO), 975 (CS), 874 (NiS) 758 (NiN). UV-Visible spectrum in DCM, nm, (M-1 cm1

): 252 (30,000), 342 (7,600), 405 (11,000). Elemental analysis calc. for C14H17S2ON5Ni:

C, 42.66, H, 4.35, N, 17.77. Found: C, 42.85, H, 4.46, N, 17.57. Mass spectrum calc. for
C14H17S2ON5Ni: 393.02281. Found: 393.0214 and 394.0295.
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Zn(MEB) (25). Compound 16 (0.354 g, 1.29 mmol) was suspended in methanol (25 mL).
To this suspension zinc(II) acetate dihydrate (0.307 g, 1.49 mmol) was added with stirring
giving a yellow-orange precipitate. The suspension was refluxed for 4 h and then cooled to
room temperature. The formed solid was filtered and then washed with methanol. Yield =
0.275 g (63%). 1H NMR, (C2D6SO, 400 MHz), δ 1.26 (t, 3H) 2.22 (s, 3H) 2.25 (s, 3H) 2.84
(3H) 4.30 (br, 2H) 7.48 (1H). 13C NMR, (C2D6SO, 100 MHz) δ 14.2, 14.9, 64.0, 110.0. IR,
cm-1: 3337 and 1557 (NH), 2930 and 1494 (CH), 1397 and 1227 (CN), 1082 (CO), 1027
(CS), 841 (ZnS), 774 (ZnN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 243 (12,000),
299 (9,900), 422 (8,700). Elemental analysis calc. for C9H15S2ON5Zn: C, 31.91, H, 4.46,
N, 20.67. Found: C, 31.92, H, 4.45, N, 20.67. Mass spectrum calc. for
C9H15S2ON5Zn: 337.00096. Found: 338.2153.
Zn(MPB) (26). Compound 26 was prepared using the same method as described for 25
from 17 (0.373 g, 1.29 mmol) and zinc(II) acetate dihydrate (0.307 g, 1.49 mmol) in
methanol (25 mL). Compound 26 was isolated as a yellow-orange precipitate. Yield =
0.424 g (93%). 1H NMR, (C2D6SO, 400 MHz), δ 0.92 (t, 3H) 1.66 (br, 2H) 2.20 (s, 3H)
2.22 (s, 3H) 2.85 (s, 3H) 4.21 (br, 2H) 7.48 (s, 1H). 13C NMR, (C2D6SO, 100 MHz), δ 10.9,
14.9, 22.3, 69.7, 110.0. IR, cm-1: 3367, 3311, and 1549 (NH), 2973 and 1491 (CH), 1372
and 1209 (CN), 1122 (CO), 1079 (CS), 836 (ZnS), 783 (ZnN). UV-Visible spectrum in
DCM, nm, (M-1 cm-1): 243 (10,000), 299 (7,400), 423 (7,500). Elemental analysis calc. for
C10H17S2ON5Zn·CH3OH: C, 34.33, H, 5.50, N, 18.20. Found: C, 33.99, H, 5.25, N, 18.12.
Mass spectrum calc. for C10H17S2ON5Zn: 351.0166. Found: 352.07.
Zn(MEP) (27). Compound 27 was prepared using the same method as described for 25
from 18 (0.435 g, 1.29 mmol) and zinc(II) acetate dihydrate (0.307 g, 1.49 mmol) in
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methanol (25 mL). Compound 27 was isolated as a yellow-orange precipitate. Yield =
0.322 g (62%). 1H NMR, (C2D6SO, 400MHz), δ 1.14 (t, 3H) 2.03 (s, 3H) 2.87 (s, 3H) 4.08
(br, 2H) 7.45 (br, 5H) 7.61 (s, 1H).
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C NMR, (C2D6SO, 100MHz), δ 14.8, 16.2, 110.0,

128.4, 129.5, 129.7, 132.9. IR, cm-1: 3351 and 1541 (NH), 2971 and 1481 (CH), 1392 and
1221 (CN), 1019 (CO), 970 (CS), 801 (ZnS), 756 (ZnN). UV-Visible spectrum in DCM,
nm, (M-1 cm-1): 269 (11,000), 326 (8,100), 430 (7,300). Elemental analysis calc. for
C14H17S2ON5Zn: C, 41.95, H, 4.27, N, 17.47. Found: C, 40.65, H, 4.08, N, 19.97. Mass
spectrum calc. for C14H17S2ON5Zn: 399.01661. Found: 400.3753.
Ni(ATSDM) (28). The ligand H2ATSDM (0.28 g, 0.96 mmol) was suspended in methanol
(25 mL). To this suspension, nickel (II) acetate tetrahydrate (0.25 g, 1.0 mmol) was added
with stirring giving a dark green-brown precipitate. The suspension was refluxed for 4 h
and then cooled to room temperature prior to being placed in a freezer overnight. The
formed solid was filtered cold and washed with water then ethanol giving a red-brown
solid. Yield = 0.293 g (88%). X-ray quality crystals were obtained by dissolving
Ni(ATSDM) in acetonitrile, which was then layered with ether and allowed to slowly
evaporate. 1H NMR, (C2D6SO, 400 MHz) δ 1.87 (s, 3H) 3.10 (s, 6H). IR, cm-1: 2910 (w)
and 1501 (s) (CH) 1366 (vs) and 1082 (m) (C-N) 1322 (vs) and 1258 (s) (C=N) 1006 (w)
(CS) 900 (m) (NiS) 783 (w) (NiN). UV-Visible spectrum in acetonitrile, nm, (M-1 cm-1):
256(23,000), 411 (11,000), 436 (11,000). Elemental analysis calc. for C10H18N6S2Ni: C,
34.80, H, 5.26, N, 24.35. Found: C, 34.57, H, 5.20, N, 24.12. Mass spectrum calc. for
C10H18N6S2Ni: 344.03878 Found: 343.80 and 344.80.
Ni(ATSM-F6) (29). The ligand H2ATSM-F6 (0.19 g, 0.48 mmol) was suspended in
methanol (20 mL). To this suspension, nickel(II) acetate tetrahydrate (0.15 g, 0.60 mmol)
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was added with stirring, giving a red-brown precipitate. The suspension was refluxed for 4
h and then cooled to room temperature prior to being placed in a freezer overnight. The
formed solid was filtered cold and washed with water then ethanol giving a red-brown
solid. Yield = 0.087 g (40%). X-ray quality crystals were obtained by dissolving
Ni(ATSM-F6) in acetonitrile, which was then layered with ether and allowed to slowly
evaporate. 1H NMR, (C2D6SO, 400 MHz), δ 1.94 (s, 3H) 4.00 (br, 2H) 8.29 (s, 1H). 13C
NMR, (C2D6SO, 100 MHz), δ 178.1, 158.8, 124.9 (q, J = 280 Hz), 46.3 (q, J = 33 Hz) 14.4.
IR cm-1: 3462 (m) (NH) 1514 (s) and 1476 (s) (CH) 1271 (s) and 1218 (m) (CN) 1138 (vs)
(CF) 941 (w) (NiS) 832 (w) (NiN). UV-Visible spectrum in acetonitrile, nm, (M-1 cm-1):
259 (24,000), 328 (8,200), 392 (9,100). Elemental analysis calc. for C10H12N6S2F6Ni: C,
26.51, H, 2.67, N, 18.55, F, 25.16. Found: C, 26.36, H, 2.59, N, 18.29, F, 25.10. Mass
spectrum calc. for C10H18N6S2Ni: 451.98223 Found: 452.87.
2.4 Crystallographic Studies
Single crystal X-ray diffraction studies were conducted on complexes 10-15, 18,
19, 21, 22, 28, and 29. The CCDC deposit numbers and references can be found in Table
2-1. Suitable crystals for X-ray diffraction of 10-15, 18, 19, 21, and 22 were grown from a
sealed tube in which dichloromethane was layered with ethanol. For 28 and 29, crystals
were grown from a sealed tube in which acetonitrile was layered with diethyl ether.
Table 2-1. CCDC and publication reference information
Compound
CCDC number
Reference
82
1517907
10
82
1517908
11
82
1517909
12
82
1517910
13
82
1517911
14
82
1517912
15
83
N/A
18
83
N/A
19
83
N/A
21
83
N/A
22
84
1866543
28
84
1866544
29

35

Crystals 10, 11, and 29 were mounted on a CryoLoop and 12 – 15 and 28 were
mounted on a glass fiber for collection of X-ray data on an Agilent Technologies/Oxford
Diffraction Gemini CCD diffractometer. The CrysAlisPro85 CCD software package (v
1.171.36.32) was used to acquire -scan exposures of data at 100K using monochromated
MoKα radiation (0.71073 Å) from a sealed tube. Frame data were processed using
CrysAlisPro85 RED to determine final unit cell parameters to produce raw hkl data that
were then corrected for absorption using SCALE3 ABSPACK.86 The structures of 10–15
were solved by Direct Methods using SHELX87 and refined by least squares methods on
F2 using SHELXL-97.87 Crystals 28 and 29 were solved by Direct Methods using
SHELXS87 and refined by least squares methods on F2 using SHELXL87 For all crystals
non-hydrogen atoms were refined anisotropically.
For crystals 11–15 and 28, all hydrogens atoms were located by difference maps
and refined isotropically. For 10 and 29 methyl hydrogen atoms were placed in their
geometrically generated positions and refined as a riding model and these atoms were
assigned U(H) = 1.5 x Ueq. The imine NH hydrogen atoms of 29 were located by difference
maps and refined isotropically. For all unique reflections the final anisotropic full matrix
least-squares refinement on F2 for all variables converged with R1, wR2, GOF as listed in
the Tables 2-2 to 2-4.
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Table 2-2. Crystal data and structural refinement for 10-13
Compound
Empirical formula
Formula weight
Temperature (K)
Wavelength (Å)
Crystal system
Space group
Unit cell dimension
a (Å)
b (Å)
c (Å)
α (°)
β (°)
γ (°)
Volume (Å3)
Z
ρcalcd. (Mg/m3)
Abs. coeff. (mm-1)
F(000)
Crystal colour, habit
Crystal size (mm3)
θ range data collection (°)
Index ranges

Reflections collected
Independent reflections
Completeness to θ max
Absorption correction
Max. and min. trans.
Refinement method
Data/restraints/params
Goodness-of-fit on F2
Final
R
indices
[I>2σ(I)]a,b
R indices (all data)
Largest difference peak
and hole (e·Å3)

10

11

12

13

C8H12CuN4O2S2
323.89
99.95(10)
0.71073
Orthorhombic
Pbcn
16.8510(16)
8.8146(7)
8.2090(8)
90
90
90

C10H16CuN4O2S2
351.93
100.05(10)
0.71073
Triclinic
P-1
8.5267(4)
8.7430(3)
10.4065(4)
80.502(3)
72.838(4)
70.532(4)

C12H20CuN4O2S2
379.98
99.95(10)
0.71073
Orthorhombic
Pbcn
22.6633(9)
9.0529(3)
7.8296(2)
90
90
90

C12H20CuN4O2S2
379.98
99.95(10)
0.71073
Monoclinic
P21/c
14.6103(8)
16.3511(6)
7.0344(8)
90
98.413(5)
90

1219.3(2)
4
1.764
2.128
660
Thin orange plate
0.18 x 0.18 x 0.03
3.60 to 25.35
-20 ≤ h ≤ 19
-10 ≤ k ≤ 9
-9 ≤ 1 ≤ 9
6029
1119
[R(int) = 0.0503]
99.8%
Multi-scan
1.000 and 0.517
Full-matrix leastsquares on F2
1119 / 0 / 80
1.072
R1 = 0.0523
wR2 = 0.0723
R1 = 0.0867
wR2 = 0.0792
0.465 and -0.537

696.95(5)
2
1.677
1.869
362
Dark purple plate
0.17 x 0.08 x 0.03
3.33 to 27.14°
-10 ≤ h ≤ 10
-11 ≤ k ≤ 11
-13 ≤ 1 ≤ 13
15161
3074
[R(int) = 0.0257]
99.8%
Multi-scan
1.000 and 0.865
Full-matrix leastsquares on F2
3074 / 0 / 236
1.049
R1 = 0.0206
wR2 = 0.0519
R1 = 0.0229
wR2 = 0.0532
0.499 and -0.347

1606.38(10)
4
1.571
1.628
788
Orange plate
0.28 x 0.07 x 0.03
3.51 to 27.09°
-29 ≤ h ≤ 26
-11 ≤ k ≤ 10
-10 ≤ 1 ≤ 10
9630
1772
[R(int) = 0.0337]
99.8%
Multi-scan
1.000 and 0.864
Full-matrix leastsquares on F2
1772 / 0 / 136
1.034
R1 = 0.0259
wR2 = 0.0637
R1 = 0.0327
wR2 = 0.0672
0.440 and -0.275

1662.40(14)
4
1.518
1.573
788
Orange plate
0.33 x 0.10 x 0.02
3.30 to 26.10°
-18 ≤ h ≤ 18
-20 ≤ k ≤ 20
-8 ≤ 1 ≤ 8
13215
3292
[R(int) = 0.050]
99.5%
Multi-scan
1.000 and 0.656
Full-matrix leastsquares on F2
3292 / 0 / 270
1.043
R1 = 0.039
wR2 = 0.079
R1 = 0.054
wR2 = 0.086
0.647 and -0.559

R1 = Σ||Fo| - |Fc||/Σ|Fo|; b wR2 = {Σ[w(Fo2– Fc2) 2]/Σ[w(Fo2) 2]}1/2; where w = q/σ2(Fo2) + (qp) 2 + bp. GOF =
S = {Σ[w(Fo2– Fc2) 2]/(n – p)}1/2, where n is the number of reflections and p is the number of parameters
refined.
a
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Table 2-3. Crystal data and structural refinement for 14, 15, 18, and 19
Compound
Empirical formula
Formula weight
Temperature (K)
Wavelength (Å)
Crystal system
Space group
Unit cell dimension
a (Å)
b (Å)
c (Å)
α (°)
β (°)
γ (°)
Volume (Å3)
Z
ρcalcd. (Mg/m3)
Abs. coeff. (mm-1)
F(000)
Crystal colour, habit
Crystal size (mm3)
θ range data collection
(°)
Index ranges

Reflections collected
Independent
reflections
Completeness to θ
max
Absorption correction
Max. and min. trans.
Refinement method
Data/restraints/params
Goodness-of-fit on F2
Final
R
indices
[I>2σ(I)]a,b
R indices (all data)
Largest
difference
peak and hole (e·Å3)

14

15

18

19

C22H40CuN4O2S2
520.24
99.95(10)
0.71073
Orthorhombic
Pbcn
30.6050(7)
9.10885(20)
9.19230(19)
90
90
90

C12H20CuN4O2S2
379.98
99.95(10)
0.71073
Monoclinic
C2/c
20.267(2)
9.1509(9)
9.0767(10)
90
102.350(12)
90

C14H19N5OS2
337.46
102.0(3)
0.71073
Monoclinic
P21/c
9.91024(14)
16.6144(2)
20.7808(3)
90
96.2668(13)
90

C18H30Cu2N10O2S4
673.84
100.1(9)
0.71073
Triclinic
P-1
8.2759(4)
10.2427(3)
16.8758(6)
74.102(3)
89.740(4)
85.364(3)

2526.60(9)
4
1.348
1.040
1108
Orange needle
0.37 x 0.07 x 0.04
3.42 to 27.14°

1644.4(3)
4
1.535
1.590
788
Orange plate
0.49 x 0.07 x 0.01
3.21 to 28.16°

3401.16(8)
8
1.318
0.322
1424
Yellow prism
0.40 x 0.35 x 0.33
3.21 to 30.55

1371.07(9)
2
1.632
1.893
692
Dark orange needle
0.31 x 0.05 x 0.05
3.36 to 28.16

-39 ≤ h ≤ 39
-11 ≤ k ≤ 11
-11 ≤ 1 ≤ 11
35054
2836
[R(int) = 0.0382]
99.8%

-26 ≤ h ≤ 26
-12 ≤ k ≤ 12
-11 ≤ 1 ≤ 12
10256
2003
[R(int) = 0.0702]
99.6%

-14 ≤ h ≤14
-23 ≤ k ≤23
-29 ≤ l ≤29
81797
10411
[R(int) = 0.0416]
99.9%

-10 ≤ h ≤10
-13 ≤ k ≤13
-22 ≤ l ≤22
25443
6693
[R(int) = 0.0306]
99.6%

Multi-scan

Multi-scan

Multi-scan

1.000 and 0.871
Full-matrix leastsquares on F2
2836 / 0 / 221
1.013
R1 = 0.0244
wR2 = 0.0618
R1 = 0.0295
wR2 = 0.0649
0.359 and -0.206

1.000 and 0.577
Full-matrix leastsquares on F2
2003 / 0 / 136
1.085
R1 = 0.0398
wR2 = 0.0937
R1 = 0.0562
wR2 = 0.1059
0.874 and -0.492

1.000 and 0.970
Full-matrix leastsquares on F2
10411 / 0 / 483
1.036
R1 = 0.387,
wR2 = 0.0825
R1 = 0.0500,
wR2 = 0.0878
0.447 and -0.377

Semi-empirical from
equivalents
1.000 and 0.673
Full-matrix
leastsquares on F2
6693 /0 / 445
1.039
R1 = 0.0385,
wR2 = 0.0767
R1 = 0.0486,
wR2 = 0.0821
1.653 and -0.923

R1 = Σ||Fo| - |Fc||/Σ|Fo|; b wR2 = {Σ[w(Fo2– Fc2) 2]/Σ[w(Fo2) 2]}1/2; where w = q/σ2(Fo2) + (qp) 2 + bp. GOF =
S = {Σ[w(Fo2– Fc2) 2]/(n – p)}1/2, where n is the number of reflections and p is the number of parameters
refined.
a
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Table 2-4. Crystal data and structural refinement for 21, 22, 28, and 29
Compound
Empirical formula
Formula weight
Temperature (K)
Wavelength (Å)
Crystal system
Space group
Unit cell dimension
a (Å)
b (Å)
c (Å)
α (°)
β (°)
γ (°)
Volume (Å3)
Z
calcd.. (Mg/m3)
Abs. coeff. (mm-1)
F(000)
Crystal colour, habit
Crystal size (mm3)
θ range data collection
(°)
Index ranges

Reflections collected
Independent
reflections
Completeness to θ
max
Absorption correction
Max. and min. trans.
Refinement method
Data/restraints/params
Goodness-of-fit- on F2
Final R indices
[I>2σ(I)]a,b
R indices (all data)
Largest difference
peak and hole (e·Å3)

21
C28H34Cu2N10O2S4
797.97
100.2(6)
0.71073
Triclinic
10.2767(5)
11.8398(5)
14.8880(6)
73.776(4)
78.850(4)
75.204(4)

22
C9H15N5NiOS2
332.09
102(3)
0.71073
Monoclinic
P21/c
7.7351(2)
20.8045(6)
8.2308(3)
90
93.119(3)
90

C10H18N6NiS2
345.13
100.2(6)
0.71073
Triclinic
P-1
7.33437(16)
8.5595(2)
11.6784
103.865(2)
98.2102(19)
91.7205(18)

C10H12F6N6NiS2
453.09
100(2)
0.71073
Triclinic
P-1
8.3598(10)
9.4027(10)
13.5112(17)
109.467
105.475(11)
91.382(9)

1667.09(13)
2
1.590
1.571
820
Orange plate
0.31 x 0.17 x 0.03
3.31 to 29.21

1322.58(7)
4
1.668
1.778
688
Thin orange plate
0.38 x 0.05 x 0.01
3.65 to 26.06

702.92(3)
2
1.631
1.672
360
Orange prsim
0.40 x 0.34 x 0.18
3.40 to 31.57

957.53(19)
2
1.571
1.291
456
Red-brown plate
0.41 x 0.08 x 0.01
3.30 to 26.67

-14 ≤ h ≤14
-16 ≤ k ≤16
-20 ≤ l ≤20
44148
8974
[R(int) = 0.0373]
99.2%

-9 ≤ h ≤9
-25 ≤ k ≤24
-10 ≤ l ≤10
11760
2601
[R(int) = 0.0316]
99.4%

-10≤ h ≤ 10
-12 ≤ k ≤12
-17 ≤ l ≤ 17

-10≤ h ≤ 10
-11 ≤ k ≤11
-17 ≤ l ≤ 17

19998
4702
[R(int) = 0.0217]
99.9 %

13904
4031
[R(int) = 0.058]
99.7%

Semi-empirical
from equivalents
1.000 and 0.792
Full-matrix leastsquares on F2
8974/0/429
1.038
R1= 0.028,
wR2= 0.0618
R1= 0.0355,
wR2= 0.0655
0.843 and -0.466

Multi-scan

Multiscan

Multiscan

1.000 and 0.939
Full-matrix leastsquares on F2
2601/1/179
1.071
R1= 0.0353,
wR2= 0.0823
R1 = 0.0405,
wR2 = 0.0846
0.619 and -0.301

1.000 and 0.778
Full-matrix leastsquares on F2
4702/0/244
1.013
R1 = 0.0196
wR2 = 0.0533
R1 = 0.0211
wR2 = 0.0545
0.525 and -0.285

1.00 and 0.678
Full-matrix leastsquares on F2
4031/0/288
1.074
R1 = 0.0500
wR2 = 0.1099
R1 = 0.0647
wR2 = 0.1188
1.176 and -0.477

P-1

28

29

R1 = Σ||Fo| - |Fc||/Σ|Fo|; b wR2 = {Σ[w(Fo2– Fc2) 2]/Σ[w(Fo2) 2]}1/2; where w = q/σ2(Fo2) + (qp) 2 + bp. GOF =
S = {Σ[w(Fo2– Fc2) 2]/(n – p)}1/2, where n is the number of reflections and p is the number of parameters
refined.
a
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2.5 Preparation of Modified Glassy Carbon Electrodes
Complexes 2, 28, and 29 (4 mg each) were dispersed in 1 mL acetonitrile (VWR,
ACS grade, dried using an MB-SPS from MBRAUN) using a vortex mixer (Vortex Genie
2, Scientific Industries). The 10% (v/v) aqueous nafion solution (12.5 μL) was then added
to the resulting ink. The dispersion was further homogenized via ultrasonication (ColeParmer Ultrasonic Bath) for 2 h. After sonication, 10 μL of the resulting dispersion was
dropped onto a glassy carbon electrode (E4TQ ChangeDisk, Pine Research), rotating at 50
RPM, affixed to a rotator (MSR Rotator, Pine Research). The rotation speed was
subsequently increased to 300 RPM, and this speed was maintained until the film dried.
2.6 Electrode Surface Characterization
Scanning electron microscopy (SEM) was carried out using a TESCAN VEGA3
microscope operating at 10 kV and 10 mA. Images of the catalyst materials were taken
using the ejectable glassy carbon electrode disk tip as the substrate. As above, catalyst
dispersion was dropped onto the glassy carbon electrode and allowed to dry over rotation.
At this point, either the disk was ejected and taken to the SEM, or the material was cycled
to peak activity (as described above) before disk ejection and characterization. Raman
spectroscopy was carried out using a Renishaw inVia spectrometer with red (632 nm) laser
(Renishaw RL 633) operating at 100% power. Samples were prepared for Raman as
described for SEM.
2.7 MTT Assay
MTT assays were performed by Dr. Sarah Andres at the University of Louisville
medical school in collaboration with Dr. Paula Bates. Anti-proliferative activity of 16-27
were evaluated using a previously published 3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT) assay protocol.88-90 Cells were seeded in
quadruplicate wells in 96-well plates and allowed to adhere overnight. To account for
intrinsic differences in growth rates, cells were plated at the following densities to
achieve comparable MTT absorbance values (OD570 between 0.5 and 1) for untreated
cells: A549, 1000 cells/well; IMR-90, 5000 cells/well. After 72 h of treatment with test
compounds, MTT (Sigma/Millipore Sigma, St. Louis, MO) was added for 4 h prior to
cell lysis. Each assay was performed in at least triplicate. All readings were normalized to
the vehicle treatment of only DMSO.
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CHAPTER III
SYNTHESES, STRUCTURES, AND ELECTROCHEMICAL STUDIES OF N,N'BIS(ALKYLTHIOCARBAMATE)BUTANE-2,3-DIIMINE CU(II) COMPLEXES AS
PENDANT ALKOXY DERIVATIVES OF CU(ATSM)
3.1 Introduction
The biological applications of 1 as a diagnostic and therapeutic agent have been
extensively studied.22-31,38 The Cu(II) ion sits in a conjugated dianionic N2S2 framework
with terminal –NHMe functional groups that do not participate in metal-ligand binding.
The key structural and electronic facets of 1 that make it ideal for biological studies are its
neutrality, planarity, and reduction potential. The rigid planarity of 1 is exemplified by the
best fit plane for all 17 non-hydrogen atoms, for which the largest deviation ±0.047 Å for
N2/N2′ with a standard deviation of ±0.025 Å.91 Along with the planarity, the complex is
neutral and is capable of diffusing across cell membranes and is only retained by gaining a
negative charge upon reduction. Compound 1 can therefore freely diffuse across cell
membranes to either enter or exit a cell under normoxic conditions. However, under the
low oxygen tension of hypoxia, 1 is reduced in the cytosol and thus preventing it from
exiting the cell, Figure 3-1. This redox selectivity of 1 has led to its evaluation as a 64Cu
and 62Cu radiopharmaceutical for selective imaging of hypoxia.27-31
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Figure 3-1. Depiction of copper retention in normoxic (A) and hypoxic (B) cells.

Further, 1 has been evaluated for the treatment of neurodegenerative diseases.22-25
Phase I clinical trials, as a therapeutic for amyotrophic lateral sclerosis/motor neuron
disease (ALS/MND) are currently underway.26 The redox selectivity is further exemplified
by comparison of 1 with the copper complexes of PTSM (+80 mV) and GTSM (+160 mV),
Figure 3-2. The CuPTSM derivative with its more anodic CuII/I couple was found to not be
retained in cells in a discriminating manner when compared to 1 for imaging. In
therapeutics, the treatment of cancer cells have been evaluated comparing 1 with CuGTSM.
Here however, it was found that 1 was ineffective in the treatment of cancer cells.38

Figure 3-2. Structural comparison of CuATSM, CuPTSM, and CuGTSM.
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The biological importance of 1 has led to the synthesis and characterization of a
large number of related copper bis(thiosemicarbazonato) complexes with symmetric and
asymmetric variation at the R1 and R2 positions, shown in Scheme 3-1.7,13,15,19,21,32-33,39-40,92
Substitution at the R1 position has largely focused on other amine derivatives to investigate
the impact on selectivity and/or reduction potential. In general, chain extension has a small
effect on the CuII/I potential.13,15 However, modification with aromatic rings can lead to
stabilization of Cu(I) by as much as +240 mV.39 Que and co-workers recently reported
symmetric and asymmetric CuATSM derivatives with the –NHMe groups replaced by –
NHCH2CF3 with stabilization of Cu(I) by ~70 mV per –NHCH2CF3. Interestingly, these
complexes allow for hypoxia imaging by

19

F MRI, thus avoiding the need for

64

Cu.32

Variation of the R2 backbone methyl groups with hydrogen or phenyl substituents also
stabilize Cu(I), with the later showing a larger effect of ~240 mV.13,39 The effect of R2
group substitution for a wide variety of functional groups was evaluated using
experimentally benchmarked density functional theory calculations of CuII/I reduction
potentials. A Hammett analysis of the theoretical CuII/I potentials is consistent with an
inductive effect where Cu(I) is stabilized by the electron-withdrawing substituents.16

Scheme 3-1. Synthesis of compounds 10-15.
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The numerous derivatives of Cu(ATSM) reported to date have by and large
maintained an N2S2 donor core with terminal amine based R1 groups. The research in this
dissertation highlights a modification to the ligand framework by incorporation of alkoxy
groups at the terminal R1 position. As outlined in Scheme 3-1, a series of six ligands and
their Cu(II) complexes have been synthesized and fully characterized. One compound was
previously synthesized and characterized by UV-visible spectroscopy.93 As detailed below,
this results in a substantial shift in the Cu(II/I) reduction potential relative to 1.
3.2 Results
3.2.1 Synthesis and Characterization
A series of N2S2 N,N′-bis(alkylthiocarbamate)butane-2,3-diimine ligands (4 – 8)
with varying O-alkyl chain lengths and N,N′-bis(methylthiocarbamate)hexane-3,4-diimine
(9) have been prepared and complexed with Cu(II) yielding the square planar complexes
10 – 15. The ligands were obtained in three steps from inexpensive bulk commodity
chemicals, Scheme 3-2.

Scheme 3-2. Synthesis of ligands 4-9.
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Using previously reported methods, xanthates were prepared from the appropriate
alcohol and carbon disulfide.79 The xanthates were subsequently condensed with hydrazine
monohydrate to yield the hydrazinecarbothioc acid O-alkyl esters.80 Condensation of the
ester with butanedione (4 – 8) or hexanedione (9) yielded the desired ligand in a reaction
similar to H2ATSM synthesis.14 Notably, all ligand syntheses were conducted open to the
atmosphere in ethanol solution with facile purification by filtration and washing. The
simplicity of these methods and the variety of available alcohols and diones make N,N′bis(alkylthiocarbamate)butane-2,3-diimine and its derivatives potentially useful new class
of ligands related to the bis-thiosemicarbazone family.
The 1H NMR of 4, seen in Figure 3-3, displays a prototypical chemical shift for
methoxy protons at δ 4.03. This chemical shift is a key identifier for this ligand class of the
protons adjacent to the oxygen near 4.00. The backbone protons occur at δ 2.11, which is
another indication of condensation. A unique feature for this subset of ligands is the two
chemical shifts at δ 11.46 and 11.77, corresponding to the imino hydrogen. BTSC analogs
display only one peak for this hydrogen. This unique pattern could potentially arise from
tautomerism, however temperature dependent NMR studies were not conducted. The 13C
NMR of 4, Figure 3-4, shows prototypical peaks of tertiary C=N and C=S carbons at δ
117.8 and 188.0, respectively. The methyl carbons of the backbone and alkoxy
functionality are present at δ 58.5 and 12.3 respectively. The remaining 1H and 13C NMR
spectra for 5-9 can be found in the appendix, Figures A1-A9.
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Figure 3-3. 1H NMR of 4 in DMSO.

Figure 3-4. 13C NMR of 4 in DMSO, with the ppm inset of a zoomed out image to display the
DMSO peak.
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The FT-IR spectrum of 4, Figure 3-5A, is representative for this class of
compounds. Key stretches are the N–H, C–O, and C=S. The C–O and C=S occur at 1137
and 1060 cm-1 in 4. The N–H stretch, at 3240 for 4, is paramount in identification. The
corresponding hydrazinecarbothioc acid O-alkyl ester, has a primary and secondary amine,
thus has multiple N–H stretches that are not present in the ligand. Further, the IR spectra
of 10–15 display no N–H stretching, indicative of deprotonation, Figure 3-5B. The loss of
these protons generates a 2– charge on the ligand, in turn creating a neutral chelate from a
metal 2+ ion. Therefore, to generate a neutral complex, a suitable base is needed to deprotonate the ligand framework. A suitable metal salt may contain a basic counter ion (i.e.,
acetate) or an exogenous base may be used. Further, the C–O and C=S stretches shift to
1091 and 948 cm-1, respectively. Lastly, upon metalation, new peaks occur in the IR
spectrum at 831 and 671 cm-1 that indicate Cu–S and Cu–N stretching. The remaining FTIR spectra can be found in the Appendix (Figures A10-A19).

Figure 3-5. FT-IR spectra of 4 (A) and its copper complex 10 (B).

The electronic spectra of 10 – 15 recorded in dichloromethane display a ligand to
metal charge transfer band near 485 nm and two more intense ligand to ligand charge
transfer bands near 248 and 290 nm. The spectrum of 10 is shown in Figure 3-6 as a
representative of the whole class of compounds. The spectra of 11–15 can be found in the
Appendix (Figures A20-A24). The transition energies are largely insensitive to the identity
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of the O-alkyl group R1 or the backbone substituent R2, Table 3-1. As shown in Table 31, the high energy bands for 10 at 246 and 290 nm are red shifted by 2340 and 2640 cm-1
with respect to the bands at 261 and 314 nm in Cu(ATSM), 1. The lower energy band of
10 at 486 nm is blue shifted by 388 cm-1 relative to the band at 477 nm in Cu(ATSM).13
The shifts are attributed to electronic differences within the ligand framework and no
solvent effects. The spectra of 10 in DCM and DMSO are not substantially different.

Figure 3-6. UV-visible spectrum of 10, representative of the class.

The EPR spectra of 10 – 15 were recorded as powders at room temperature.
Complexes 10 – 15 are expected to be square planar with an unpaired electron in the dx2-y2
orbital. The unpaired electron could undergo transitions to the dxy, dxz, and dyz orbitals.
Since the dxz and dyz are degenerate in a square planar environment, only two transitions
are expected to be observed with the dxz/yz transition twice the intensity. As shown in Figure
3-7 complex 12 displays an axial spectrum with g|| > g > 2 (Table 3-1) consistent with
square planar Cu(II) and a single unpaired electron located in dx2-y2. The remaining spectra
can be found in the Appendix (Figures A25-A29). Simulated values for g|| and g fall in
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the narrow ranges of 2.031 – 2.042 and 2.089 – 2.131, respectively, consistent with the
similarities observed for 11 – 15 in the electronic spectrum. The spectrum of 10 is too broad
to resolve the axial signal, but the observed g-value of 2.061 is near the average g-values
of the other complexes.

Figure 3-7. Experimental (solid black line) and simulated (dashed red line) EPR spectrum of 12.
This spectrum is representative of the whole class of compounds.

A comparison of the EPR and UV-visible data shows only small changes in the
spectroscopic features of complexes 10 – 15 as compared to similar bis-thiosemicarbazone
analogues, 1 and 30 – 33. The axial EPR spectra of 1, Cu(ATSM), is indistinguishable from
those of 11 – 15. The reported g|| and g values of 2.115 and 2.038 for 1 fall within the
narrow ranges of 2.031 – 2.042 and 2.089 – 2.131 for 11 to 15, Table 3-1, indicating no
significant changes in the relative energies of the d-orbital manifold.
3.2.2 Electrochemical Studies
The cyclic voltammograms of 10 – 15 in dichloromethane, each show two
reversible events assigned to CuIII/II and CuII/I couples, Table 3-1. The E1/2 values for the
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CuIII/II and CuII/I events of 10 are observed at +585 and –857 mV versus
ferrocenium/ferrocene, respectively, Figure 3-8. The remaining voltammograms can ebe
found in the Appendix (Figures A30-A34). Variation of the side-chain R1 and backbone
R2 groups modulates the CuII/I reduction potential. Increasing the length of the R1 from –
OMe to –OEt and –OnPr systematically decreases the CuII/I potential of 11 and 12 to –879
and –892 mV, respectively. Further chain extension to –O-octyl, 14, slightly increases the
potential to –884 mV. Substitution of –OnPr with –OiPr further destabilizes Cu(I) as
indicated by the CuII/I potential of 13 at –904 mV. Changes at the R2 slightly influence the
reduction potential as shown by a comparison of 11 and 15, with the former more difficult
to reduce by 5 mV.

Figure 3-8. Cyclic voltammogram of 10 in CH2Cl2 with 0.1 M tetrabutylammonium
hexafluorophosphate as supporting electrolyte. Scan rate = 100 mV/s; potentials referenced
versus Fc+/Fc.
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A comparison of the methylamine derivative 1 with the methoxy derivative 10
shows a +253 mV shift in the CuII/I reduction potential. A similar shift of +241 mV is
observed upon substitution of –NHEt (34) with –OEt (11). These large shifts can be
attributed to an inductive effect consistent with the electron withdrawing properties of the
alkoxides and prior Hammet analysis of the –NHR functional group effect on reduction
potentials.16 Extension of the carbon chain in the R2 position from Me to Et results in a 5
mV increase from compound 11 to 15, whereas the related bis-thiosemicarbazone
analogues 1 and 36 show an increase of 10 mV confirming the new class of compounds
follow the same electrochemical trend. This difference in reduction potential would
indicate that this new class of compounds would not be ideal for imaging given the ease of
accessibility. However in comparison with 35, which as previously mentioned has potential
therapeutic properties, this new class of compounds has a more anodic CuII/I potential by
approximately 100 mV. Thus, these compounds could be useful in the treatment of cancer.
Unfortunately, these compounds are only soluble in DCM, which is not suitable for
biological studies. In total, six new complexes with CuII/I reduction potentials in the range
of -904 mV to -857 mV have been prepared demonstrating that substitution of –NHR with
–OR yields a large anodic shift in the Cu(II/I).

52

53

Table 3-1. UV-visiblea, EPRb, and electrochemicalc data for N,N′-bis(alkylthiocarbamate)butane-2,3-diimine Cu(II) complexes 7 – 12
and selected Cu(ATSM) derivatives.
Complex
R1
R2
CuIII/II
CuII/I
Ref.
maxa
g||, g
b
(nm) (ε)
(gavg)
E1/2 (ipc/ipa
E1/2 (ipc/ipa
(mV)c
(mV)c
OMe
Me
246 (16,000) 290 (20,000)
(2.061)
585 (0.934)
-857 (0.941)
77
10
486 (2,680)
OEt
Me
248 (16,300) 290 (22,700)
2.131, 2.036 (2.068)
528 (0.933)
-879 (0.965)
77
11
485 (2,920)
OnPr
Me
248 (16,600) 291 (23,800)
2.127, 2.034 (2.065)
542 (0.964)
-892 (0.997)
77
12
484 (2,930)
OiPr
Me
248 (16,500) 292 (23,600)
2.089, 2.042 (2.058)
505 (0.867)
-904 (0.964)
77
13
484 (3,210)
O-octyl
Me
248 (15,900) 291 (23,600)
2.130, 2.034 (2.066)
545 (0.929)
-884 (0.867)
77
14
485 (3,100)
OEt
Et
249 (18,300) 292 (25,000)
2.124, 2.031 (2.062)
549 (0.934)
-874 (0.975)
77
15
485 (3,340)
13a,c 8b
NHMe
Me
261 314 477
2.113, 2.029 2.026 (2.056)
200
-1110
1
13
NH2
Me
263 310 477
N/A
-180
-1110
30
8
NMe2
Me
320 450 490 525
2.085 2.033 2.024 (2.047)
N/A
N/A
31
39
N(C4H8)
Me
321 368 515 566
N/A
N/A
-1050 (1.03)
32
39
NPhMe
H
323 381 512 567
N/A
N/A
-700 (0.99)
33
94
NHEt
Me
N/A
N/A
N/A
-1120d
34
13
NHMe
H
194 262 324 495
N/A
N/A
-950
35
13
NHMe
Et
194 267 316 483
N/A
190
-1100
36
a) Electronic spectra measured in CH2Cl2 (10 – 15), DMSO (1, 30, 35, 36), or DMF (31 - 33) solution b) Powder EPR spectra collected
on solids at room temperature (10 –15, 1, 31); gavg = 1/3[g|| + 2g]. c) Electrochemical potentials versus Fc+/Fc measured versus an internal
standard in CH2Cl2 with 0.1 M nBu4NBF4 (10 – 15) or calculated from reported potentials versus Ag/AgCl in DMSO with 0.1 M nBu4NBF4
(1, 30, 35, 36) or versus SCE in DMF with 0.1 M nBu4ClO4 (32, 33) using the following conversions: E1/2 = -0.52 for Fc+/Fc vs. Ag/AgCl
in DMSO; = E1/2 = -0.51 for Fc+/Fc vs. SCE in CH2Cl2 (10 – 15), DMSO (1, 30, 35, 36), or DMF (32, 33). d) Reported as 10 mV more
negative than 1.

3.2.3 Crystallographic Studies
X-ray quality diffraction crystals of 10 – 15 were obtained as orange needles or
plates upon slow evaporation of a dichloromethane solution of the complex layered with
ethanol. Crystal data and structure refinement details are listed in the Chapter 2, Tables 22 to 2-3. All complexes crystallize as discrete, square planar Cu(II) complexes with no
solvent molecules in the crystal lattice. An ORTEP representation of 10 is shown in Figure
3-9 with selected bond distances and angles provided in Table 3-2. The structures of 11 –
15 are highly similar to 10 with core structure bond distances and angles statistically
indistinguishable from those in 10 (see Chapter 2 for CCDC deposit number). The
following discussion of 10 is representative of the entire group of complexes.

Figure 3-9. ORTEP95 view (50% probability) of 10 showing atom labeling for all non-hydrogen
atoms in the asymmetric unit and symmetry generated (1-x, -y, 1/2-z) donor atoms.

The Cu of 10 occupies an N2S2 square plane provided by the N,Nbis(methylthiocarbamate)butane-2,3-diimine ligand with Cu–N1 and Cu–S1 bond
distances of 1.958(4) and 2.2498(12) Å, respectively. The S1 and N1 donors are symmetry
generated as Cu1 sits on the special position (0.5, y, 0.25) in the orthorhombic space group
Pbcn. A similar phenomenon occurs in 12, 14, 15, whereas in 11 and 13 the asymmetric
unit contains independent atoms in the entire complex. Within the chelate ligand, bond
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distances are consistent with a conjugated π-system. One bonding MO representation can
be seen in Figure 3-10. The C3–S1, N1–N2, and C1–C1 bond distances of 1.741(5),
1.384(5), and 1.484(8) Å, respectively, are typical of single C–S, N–N, and C–C bonds.
The shorter N1–C1 and N2–C3 bond distances of 1.295(5) and 1.301(6), respectively,
reveal C=N character. The sum of the four bond angles about the Cu is 360.0(3)°.

Figure
3-10.
Representation of
the
conjugated
-network of
the
N,N′bis(alkylthiocarbamate)butane-2,3-diimine ligand of 10 highlighting localization of the C=N
bonds.

Table 3-2. Selected bond distances (Å) and bond
angles (°) for 10 and 196 as representative
examples of Cu(alkoxythiocarbamidates) and
Cu(thiosemicarbazonates), respectively.a
Bond Distance
10
1
Cu-N1
1.958(4)
1.9584(16)
Cu-S1
2.2498(12)
2.2453(5)
N1-N2
1.384(5)
1.369(2)
N1-C1
1.295(5)
1.300(2)
N2-C3
1.301(6)
1.325(3)
S1-C3
1.714(5)
1.760(2)
C1-C1′
1.484(8)
1.474(3)
C3-O1
1.331(5)
b
C3-N3
1.338(3)
Bond Angle
N1-Cu-S1
85.00(11)
85.11(5)
N1-Cu-N1′
79.9(2)
80.61(7)
S1-Cu-S1′
110.12(7)
109.21(2)
a) Atom labels for both complexes correspond to the
numbering scheme of 10 in Figure 1. b) N3 is the
nitrogen of R1 group NHCH3.
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Complex 10 is rigorously planar with the largest deviation from the best fit plane
of all 17 non-hydrogen atoms of ±0.118 Å for C3/C3 and a standard deviation of only
0.061 Å. This high degree of planarity extends throughout the whole range of complexes
including the –O-octyl derivative, 14 (Figure 3-11). For 14, the best fit plane of all 31 nonhydrogen atoms of ±0.364 Å for C4/C4 and a standard deviation of 0.258 Å. A comparison
of the structural parameters of 10 and 1 provide a representative example of the similarities
and differences of the N,N-bis(alkylthiocarbamate)butane-2,3-diimine and bisthiosemicarbazone complexes. The selected bond distances and angles in Table 3-2 reveal
a highly similar structural core. The Cu–N1 and Cu–S1 bond lengths in 10 of 1.958(4) and
2.2498(12) Å, respectively, are statistically equivalent with the values of 1.9584(16) and
2.2453(5) Å in 1. Within the ligand framework, the bond distances are also statistically
similar. Both complexes exhibit bond distances consistent with alternating single and
double bonds in an extended conjugated network as depicted in Figure 3-9 for 10. A
comparison of bond angles associated with the metal-ligand core of 10 and 1 reveals values
that are statistically equivalent or that vary less than one degree.

Figure 3-11. ORTEP95 view (50% probability) of 14 showing atom labeling for all non-hydrogen
atoms in the asymmetric unit and symmetry generated (1-x, -y, 1/2-z) donor atoms.

The degree of structural similarity makes these compounds promising for biological
applications. As previously established, the structural properties of 1 and analogous
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compounds make these BTSC’s suitable for diagnostic and therapeutic uses. The
electrochemical properties distinguish compounds as suitable or unsuitable for therapeutic
and diagnostic uses. Thus rendering the ability to maintain structural integrity with
variation in the reduction potential crucial for further development of this class of
compounds.
3.3 Conclusions
In summary, a new class of N,N-bis(alkylthiocarbamate)butane-2,3-diimine
ligands and their Cu complexes have been reported as derivatives of bisthiosemicarbazones. Substitution of the terminal –NHR functional group with –OR allows
tuning of the CuII/I and CuIII/II reduction potentials with minimal impact on the physical and
electronic structures of the complexes. The lack of appropriate solubility limits their
biological applications and restoration of a hydrogen bond donor may increase the
solubility in desired solvents. The ease of synthesis of these new ligands and the wide
variety of commercially available alcohols and diones provides for a large variety of new
bis-thiosemicarbazone like complexes for future development. Notably, the synthetic
methodologies developed in this work will be applied in the synthesis of the hybrid
complexes discussed in Chapter 5. The hydrazinecarbothioc acid O-alkyl esters can be
condensed with a mono-keto-thiosemicarbazide to generate the hybrid complex.
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CHAPTER IV
EFFECT OF STACKING INTERACTION ON THE TRANSLATION OF
STRUCTURALLY RELATED BIS-THIOSEMICARBAZONE NI(II) HER
CATALYSTS TO MODIFIED ELECTRODE SURFACES
4.1 Introduction
Increasing worldwide demand for cheap energy has fueled the need to develop
sustainable alternative energy sources.97 Hydrogen offers great potential as a carbon-free
alternative to fossil fuels.98 One of the major challenges in this area is the development of
artificial water splitting catalysts based on solid state materials and molecular based
electrocatalysts that efficiently produce O2 and H2 from water utilizing either solar
energy99-102 or electrolysis.103-104 Platinum based catalysts are the gold standard catalyst for
HER in aqueous acidic solutions. However, its practical widespread utility in
electrocatalytic devices is limited by its scarcity and high cost.105-106 This has stimulated
development of new electrocatalysts containing earth-abundant transition metals, such as
Fe,107 Co,108-110 Ni,111-114 Cu,115 and Mo,116-118 as metal phosphides,108,119 selenides,120
sulfides,121-122 and small molecule complexes.12,34-35,74,123-125 Of these materials,
molybdenum sulfides stand out as an economical alternative to Pt.126-128 Their high activity
is thought to arise from the location and number of cis-sulfur edge sites in their layered
structures.128
There is consensus that most homogenous molecular electrocatalysts generate
reactive metal-hydride intermediates during HER.35,129-132 Several of these electrocatalysts
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display low overpotential, high turnover frequencies, and Faradaic efficiencies in
excess of 90%.132-133 There is an emerging interest in the modification of electrode surfaces
with small molecule HER catalysts.109-110,134-136 Most notable, Fontecave and coworkers
developed multi-walled carbon nanotube [Ni(PPh2NPh2)2] modified electrodes that display
high catalytic activity at low overpotential.29 The Grapperhaus lab previously reported the
translation of activity and mechanism of a rhenium-thiolate HER catalyst from solution to
modified electrodes.137 Other examples of heterogeneous molecular catalysts for HER
include Co(dmgBF2)2(CH3CN)2)/carbon black (CB)/Nafion coated GC

135

and

cobaloximes modified electrodes,135-136 as well as, cobalt porphyrin,138 metalphthalocyanine,139-142 and an organometallic complex incorporated in a Nafion film.143
However, these complexes either require high overpotential and/or are unstable over
prolonged electrolysis reducing their practical use as HER catalysts.
Recently, the Grapperhaus lab and others have explored the use of
thiosemicarbazone ligands in the design of new HER electrocatalysts.10,12,34-35,76 The
thiosemicarbazone ligands are redox non-innocent and can function as a reservoir for
charge with hydrogen evolution at either the metal or ligand. The HER mechanism
proceeds via ligand-assisted metal-centered,144 ligand-centered,10,145-146 or metal-assisted
ligand-centered reactivity depending on the identity of the metal.74,145,147 Herein, in
collaboration with Alex Gupta and Dr. Gautam Gupta of the University of Louisville
Engineering School, we report the synthesis, characterization, and electrocatalytic behavior
of a series of structurally related bis-thiosemicarbazone Ni(II) complexes, deposited on
carbon electrode surfaces. The ligands are obtained in high yields using readily available,
inexpensive organic reagents according to literature methods.8,32 The resulting Ni(II)
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complexes have been characterized by NMR, FT-IR, and UV-vis spectroscopies, X-ray
crystallography, and cyclic voltammetry in acetonitrile prior to deposition on glassy carbon
electrodes (GCEs). Drop casting acetonitrile solutions of the Ni complexes on GCEs
produce uniform coatings that were characterized by spectroscopic and microscopy
methods before and after HER catalysis in aqueous acidic solutions.
4.2 Results
4.2.1 Synthesis and Characterization
The ligands H2ATSM,8 H2ATSDM,32 and H2ATSM-F632 were prepared as
previously reported. The Ni(II) complexes 2, 28, and 29 were synthesized using the
established methodology for the preparation 2.8 The newly reported 28 and 29 were
characterized by elemental analysis, cyclic voltammetry, mass spectrometry, and NMR,
FT-IR, and UV-visible spectroscopies. The 1H NMR spectra of 28 and 29, Figure 4-1 top
and bottom respectively, are consistent with their proposed structures. The protons of the
methyl group of the backbone, remained largely unchanged between 28 and 29 with δ
values of 1.87 and 1.94 respectively. The terminal methyl protons of 28 (δ 3.10) are
substantially upfield of the methylene protons of 29 (δ 4.00). Lastly, 29, displayed the
amine proton at δ 8.28. This proton is not observed in 28 due to the presence of the dimethyl
functionality, giving rise to the integration of the peak at δ 3.10 being twice that of 1.87.
The IR spectra of 28, Appendix, Figure A35 lacks the N–H stretching, indicative
of chelation, because the metal displaces the proton. Further, it is concluded by the presence
of Ni–S and Ni–N stretches at 900 and 783 cm-1, respectively, that the metalation was
successful. The FT-IR of 29, Figure 4-2, displays the prototypical N–H stretch at 3462 cm1

due to the presence of the pendant secondary amine. The –CF3 functionality gives rise to
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a C–F stretch at 1138 cm-1. Lastly, there is again the Ni–S and Ni-N stretches at 941 and
832 cm-1 respectively.

Figure 4-1. 1H NMR of 28 (top) and 29 (bottom) in DMSO.
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Figure 4-2. FT-IR of 29 as a powder (ATR).

All of the complexes gave green solutions in acetonitrile. The ligand-to-ligand
charge transfer transitions8 in the UV-visible spectrum slightly increase in energy from 28
(411 and 436 nm) to 2 (398 nm) to 29 (392 nm), Figure 4-3. The change in the ligand to
ligand charge transfer band exemplifies the effect of the functional group of the pendant
amine. The energies increase from the most electron donating group, dimethyl, to the
electron withdrawing group, –CH2CF3. Further, the ligand to ligand charge transfer band
for 28 displays two λmax values at 411 and 436 nm. This feature appears to be absent in 2
and 29; however, the peak of 2 at 398 nm appears asymmetrical, indicating the possibility
of a similar effect of two ligand-to-ligand charge transfer bands present. The spectrum of
29 does not readily display this feature. All complexes display similar π to π* transitions
at 256 nm.
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Figure 4-3. UV-visible spectra of 2 (black dots), 28 (solid blue), and 29 (dashed red) in
acetonitrile.

4.2.2 Crystallography
The solid state structures of 28 and 29 were determined by single crystal X-ray
diffraction for comparison with the known structure of 2.96 Crystals of 28 and 29 were
obtained as orange prisms and red brown plates, respectively, via slow evaporation of an
acetonitrile solution layered with ether. Crystallographic data and structure refinement
details are listed in the Chapter 2, Table 2-4. The crystal lattices of 2 and 29 include an
acetonitrile molecule, while the lattice of 28 is not solvated.
The ORTEP95 representations of 28 and 29 in Figure 4-4(top) and 4-4(bottom),
respectively, show that each contains a square planar Ni(II) in an N2S2 donor environment.
Selected bond distances and angles for 2, 28, and 29 are provided in Table 4-1. The Ni–N
distances are statistically equivalent over the series with an average value of 1.856(5) Å.
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Further, there is no significant differences in the Ni–S bond distances, which have an
average value of 2.1568(18) Å. The similarities in metric parameters are also observed in
the bond distances within the ligand framework. For all three Ni complexes, the bond
distances are consistent with a conjugated π-system of alternating single and double bonds.

Figure 4-4. ORTEP95 view (50% probability) of 28 (top) and 29 (bottom) showing atom labeling
for all non-hydrogen atoms in the asymmetric unit.
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Table 4-1. Selected bond distances (Å) and bond angles (°) for 2,96 28, and 29.
Bond distance
2a
28
29
Ni–N1
1.861(2)
1.8528(8)
1.854(3)
Ni–N3
1.855(2)
1.8580(8)
1.863(3)
Ni–S1
2.1546(6)
2.1617(3)
2.1542(11)
Ni–S2
2.1598(7)
2.1576(2)
2.1527(10)
S1–C5
1.767(3)
1.7665(9)
1.763(4)
N2–C5
1.315(3)
1.3222(12)
1.308(5)
N1–N2
1.378(3)
1.3694(11)
1.381(4)
N1–C1
1.303(3)
1.3038(11)
1.310(5)
C1–C3
1.489(4)
1.4857(13)
1.487(5)
C1–C2
1.470(3)
1.4658(13)
1.474(5)
N5–C5
1.339(3)
1.3456(12)
1.350(5)
N5–C7
1.449(3)
1.4570(13)
1.440(5)
Bond angle
N1–Ni–S1
87.07(6)
87.09(3)
87.35(10)
N1–Ni–N3
83.59(9)
83.66(4)
83.65(13)
S2–Ni–S1
101.81(3)
102.019(10)
101.94(4)
a
Metric parameters for 2 are reported according to the atom labeling scheme in Figure
4-4, which differs from prior structural report.96
Overall, the structures of 2, 28, and 29 are best described as square planar. Both 2
and 28 are rigorously planar with all non-hydrogen atoms in or near the best-fit plane. For
2, the best fit plane of all 17 non-hydrogen atoms has a standard deviation of ±0.032 Å
with the largest deviation of ±0.067 Å for S2. Similarly, in 28, the standard deviation from
the best fit plane of all 19 non-hydrogen atoms is ±0.053 Å with the largest deviation of
±0.126 Å for C3. The pendant –CH2CF3 groups of 29 disrupt the overall planarity of that
molecule. However, with the exception of the –CF3 moieties the non-hydrogen atoms
define a plane with a standard deviation of ±0.033 Å and a largest deviation of ±0.083 Å
for S2. The –CF3 carbon atom C8 sits 1.46 Å above the best fit plane for 29, whereas C10
lies 1.43 Å below the plane. The deviation of planarity caused by the CF3 moiety can be
seen in Figure 4-5.
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Figure 4-5. Ball and stick representation of 29 exemplifying the deviation of planarity caused by
the CF3 group.

The crystal packing arrangements for the rigorously planar 2 and 28 display similar
columns of paired complexes stacked along the a-axes, Figure 4-6. The bulkier –CH2CF3
groups in 29 preclude complex pairing resulting in long range stacking along the b-axis.
For 2, the “inverse pair” of complexes containing Ni (x, y, z) and Ni′ (1 – x, 1 – y, 1 – z)
stack with an interplanar distance of 3.48 Å. These inverse pairs form a column of
complexes generated by translation along the a-axis. The interplanar distance between Ni′
(x, y, z) and Ni′′ (1 + x, y, z) is 3.47 Å. Neighboring columns, with equivalent spacings, are
generated by the 21 screw axis (Ni′′′) and c-glide (Ni′′′′) associated with the P21/c space
group. Complex 28, which crystallizes in the space group P-1, displays similar columns
generated by translation of the inverse pair Ni (x, y, z) and Ni′ (1 – x, 1 – y, 1 – z) along the
a-axis with interplanar distances of 3.54 and 3.37 Å for Ni/Ni′ and Ni′/Ni′′, respectively.
The crystal packing of 29 is unique as the bulkier –CH2CF3 groups prevent stacking of
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inverse pairs. As shown in Figure 4-6, Ni (x, y, z) and Ni′ (1 – x, 1 – y, 1 – z) are contained
in separate, neighboring columns directed along the b-axis. In contrast to 2 and 28, the
interplanar distances for the columns of 29 are long, 9.40 Å, as each member of the column
is generated by a translation in the b-direction.

Figure 4-6. Packing diagrams for 2 (top), 28 (middle), and 29 (bottom). Individual labels are
associated with the following symmetry operations: Ni, E (x, y, z); Ni′, i (1 – x, 1 – y, 1 – z), Ni′′,
translation along a (1 + x, y, z) for 2 and 28 or along b (x, 1 + y, z) for 29; Ni′′′, 21 (1 –x, 0.5 + y, 1.5
- z); Ni′′′′, c-glide (x, 1.5 - y, 0.5 + z).
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4.2.3 Homogeneous Electrochemical Characterization
Cyclic voltammograms of 2 and 28 – 29, Figure 4-7, show two reversible events at
potentials more cathodic than -1.3 V vs. Fc+/Fc in acetonitrile containing 0.1 M
tetrabutylammonium hexafluorophosphate (TBAHFP) as supporting electrolyte. Density
Functional Theory calculations performed by Artero and co-workers35 assigned the more
anodic event to a ligand-centered reduction and the more cathodic event to the Ni(II/I)
redox couple, Table 4-2. The ligand and metal centered E1/2 values for 2 occur at –1.73 V
and –2.31 V vs. Fc+/Fc, respectively. The pendant secondary amines of 2 are replaced with
tertiary amines in 28 resulting in an ∼30 mV cathodic shift in the ligand-centered reduction
potential, –1.76 V. This is similar to corresponding 20 mV shift observed for CuATSDM
relative to CuATSM.13 The Ni(II/I) event of 28 does not shift compared to 2. The –CH2CF3
functionalities of 29 result in a 160 mV anodic shift of the ligand-centered event to –1.57
V. The Ni(II/I) couple of 29 is similarly shifted to –2.18 V. The magnitude of the shift is
in good agreement with Que and co-workers’ copper derivatives, which displayed ∼70 mV
anodic shift per –CF3 group when compared to CuATSM.32

Figure 4-7. Cyclic voltammograms of 2 (black trace), 28 (blue trace), and 29 (red trace) in
acetonitrile at 1 mM concentration with 0.1 M TBAHFP as supporting electrolyte. Scan rate = 200
mV/s; potentials referenced versus Fc+/Fc.
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Table 4-2. Reduction potentials versus Fc+/Fc and peak separation for 2 and 28– 29 in
acetonitrile containing 0.1 M TBAHFP as supporting electrolyte.
L/L- E1/2 (V) ΔE (mV)
Ni(II/I) E1/2 (V) ΔE (mV)
Complex
–1.73 (78)
–2.31 (84)
2
–1.76 (68)
–2.31 (73)
28
–1.57 (67)
–2.18 (78)
29
4.2.4 HER Activity of Modified Electrodes
Modified electrodes GC-1 – GC-3 were prepared by mixing 4 mg of 2, 28, or 29
respectively, and 12.5 μL of a 10% aqueous Nafion solution with 1 mL acetonitrile. The
resulting suspension was homogenized via ultrasonication, and 10 μL of the suspension
was applied dropwise to the surface of a glassy carbon electrode. The suspension was
allowed to dry on the electrode with rotation at approximately 300 RPM. The freshly
prepared modified electrodes required high overpotential of ~700 – 750 mV to reach a
current density of 10 mA/cm2 (the metric for comparing catalysts for water-splitting
applications148-149) upon immersion in 0.5 M H2SO4 indicating poor initial catalytic
activity.
The modified electrodes were then conditioned by reductive cycling. For GC-1 the
overpotential decreases from 0.697 V to 0.451 V, Figure 4-8A. Similarly, the overpotential
for GC-2 decreases from 0.703 V to a minimum of 0.446 V, Figure 4-8B. The large shift
of ~0.250 V represents a dramatic improvement in catalytic efficiency. Prior to
conditioning, the Tafel slopes for GC-1 and GC-2 are 91 and 72 mV/decade, respectively.
Following conditioning, the Tafel slopes for GC-1 and GC-2 increase only slightly,
Figures 4-8D and 4-8E, suggesting the mechanism has not significantly changed. In
contrast, conditioning does not improve the overpotential for GC-3, Figure 4-8C. In fact,
the Tafel slope for GC-3, Figure 4-8F, increases dramatically from 53 to 167 mV/decade
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upon reductive cycling. This drastic change in electrode kinetics can be attributed to either
a change in the active site or leaching of 29 into the electrolyte.

Figure 4-8. Effects of reductive cycling from 0 to -0.8 V vs. RHE at 50 mV/sec on the performance
of the three modified electrodes. (A) polarization curves for GC-1 exhibits peak HER performance
after 300 cycles. (B) polarization curves for GC-2 exhibits peak HER performance after 200 cycles.
(C) polarization curves for GC-3 exhibits peak performance after 1000 cycles. (D) Tafel slopes for
GC-1 before and after 300 cycles. (E) Tafel slopes for GC-2 before and after 200 cycles. (F) Tafel
slopes for GC-3 before and after 1000 cycles.

The experimentally determined Tafel plot is taken as the tangent to the onset region
of the polarization curve. The onset region is traditionally defined as the region where the
current is increasing while in between values of 0.5–2 mA/cm2. The slope of this line is
−𝛼𝑛𝐹

dictated by the equation 𝑠𝑙𝑜𝑝𝑒 = 2.3𝑅𝑇 where R,T, n, F, and α are the ideal gas constant,
absolute temperature, moles of electrons transferred, Faradays constant, and transfer
coefficient. For heterogeneous HER, Tafel plots provide insight into the mechanism of
catalysis. From the determined Tafel slope, the rate-determining step is determined. The
first step of any heterogeneous HER reaction is the Volmer step (120 mV/decade) which
is the absorption of a proton to the modified electrode surface. From here, the mechanism
can proceed one of two ways if the Volmer step is not rate limiting. The catalysis can

70

involve the adsorbed hydrogen reacting with a free proton in solution, Heyrovsky step (40
mV/decade) or combination of two absorbed hydrogen atoms, Tafel step (30 mV/decade)
to evolve H2, as seen in Scheme 4-1.

Scheme 4-1. Representations of the rate determining steps for heterogeneous HER and their
corresponding Tafel slopes.

Extended reductive cycling beyond the point of conditioning was used to probe the
stability of GC-1 – GC-3, Figure 4-8. No significant changes in Tafel slopes were observed
over long-term cycling, suggesting no change in reaction kinetics.150 Only a minor increase
in overpotential, ~40 mV, was observed, consistent with a small amount of catalyst
leaching into the electrolyte. For GC-1, the overpotential increases from the optimized
value of 0.451 V after 300 cycles to 0.486 V after a total of 1000 cycles, Figure 4-9A.
Similarly, for GC-2 the overpotential increases from 0.446 V after 200 cycles to 0.499 V
after 1000 cycles, Figure 4-9B. After 1000 total cycles, the Tafel slopes for GC-1 and GC2, Figure 4-9D and 4-9E respectively, increase slightly. For GC-3, the overpotential
increases from 0.740 V after 1000 cycles to 0.780 V after 1500 cycles, Figure 4-9C, with
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no significant change in Tafel slope, Figure 4-9F. The relative consistencies of the
overpotential and Tafel slope over extended reductive cycling indicates this class of
modified electrodes exhibits high durability for HER catalysis.
A comparison of modified electrode performance for GC-1 – GC-3 at peak
electrochemical activity is summarized in Figure 4-10. The polarization curves, Figure 410A, show negligible differences in HER overpotential for GC-1 and GC-2. Both of these
modified electrodes are superior to GC-3 by nearly 0.3 V. The Tafel slopes, Figure 4-10B,
for GC-1 and GC-2 of 97 mV/dec and 89 mV/dec, respectively, suggest that neither proton
adsorption or H2 diffusion from the active sites are rate limiting steps.117,151 The ratelimiting step is most likely the reaction of a solution proton with Ni-bound hydride to form
H2 gas. The large Tafel slope of 167 mV/dec for GC-3 that implies proton adsorption is
the rate-limiting step for HER catalyzed by this modified surface.152

Figure 4-9. Effects of reductive cycling from 0 to -0.8 V vs. RHE at 50 mV/sec on the performance
of the three modified electrodes past peak activity. (A) polarization curves for GC-1, revealing that
its performance diminishes following 300 cycles. (B) polarization curves for GC-2, revealing that
its performance diminishes following 200 cycles. (C) polarization curves for GC-3, revealing that
its performance diminishes following 1000 cycles. (D) Tafel slopes for GC-1 at 300 and 1000
cycles. (E) Tafel slopes for GC-2 at 200 and 1000 cycles. (F) Tafel slopes for GC-3 at 1000 and
1500 cycles.
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20
Figure 4-10. HER performance of three nickel compounds evaluated following reductive cycling
to the point of peak catalytic activity. Polarization curves (A) show the onset of hydrogen evolution
and the overpotential required for each modified electrode to reach a current density of 10 mA/cm2.
Tafel plots (B) show the current response to increasing overpotential throughout the onset period.

This poor activity of 29 was perplexing since the mechanism of the NiBTSC’s is
proposed to be reduction first. This should then lead to 29 being the best catalyst since its
reduction potentials are significantly more accessible than the other two catalysts.
However, these assumptions are predicated on homogeneous catalysis. To investigate if 29
displayed better performance in homogeneous systems, 2, 28, and 29 were subjugated to
identical homogeneous catalysis conditions, Figure 4-11.

Figure 4-11. Cyclic voltammograms of 2 (black trace), 28 (blue trace) and, 29 (red trace) in
acetonitrile at 1 mM concentration, with 0.1 M tetrabutylammonium hexafluorphospate supporting
electrolyte, 16 μL of acetic acid at a scan rate of 200 mV/s.
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From Figure 4-11 it is observed that under identical conditions, 29 displays a slight
cathodic shift in peak catalytic current. Interestingly, 29, has a more anodic reduction event
after -1.5 V compare to that of 2 and 28. Overall, these differences are minute and would
not lead to the substantial differences in HER activity upon deposition on an electrode
surface. Recently, Zhang et al. examined the effect of the electrode surface before and after
reductive cycling of BTSC catalyst which revealed significant changes in morphology.77 It
is believed the surface morphology changes cause the drastic differences.
4.2.5 Surface Characterization of Modified Electrodes
To investigate the effect of conditioning by reductive cycling, the surfaces of GC1 – GC-3 were visually characterized using SEM. Prior to conditioning, the images of GC1, Figure 4-12A, and GC-2, Figure 4-12B, show microcrystalline coatings. The crystal
morphology is the same as the single crystals of 2 and 28 investigated by X-ray diffraction.
The deposited compounds were cycled to their peak activity as established previously, to
examine the surface at optimum catalysis. After conditioning, the surface of GC-1 lacks a
crystalline appearance and resembles an amorphous microporous network, Figure 4-12D.
A similar trend is observed for GC-2. Although the overall crystalline appearance remains
intact after conditioning, Figure 4-12E, there is observable degradation of the crystalline
edges and faces, Figure 4-13. In both cases, conditioning disrupts the crystal packing and
reorders the catalyst on the electrode with an increase in surface area, which results in more
exposed active sites. The morphology of GC-3 is very different from that of GC-1 and
GC-2. Prior to conditioning, the appearance of the GC-3 surface, Figure 4-12C, is
reminiscent of the thin plates of 29 used for single crystal X-ray diffraction studies.
Following conditioning, the surface structure displays a fractured, plate-like appearance
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(Figure 4-12F) consistent with loss of complex from the surface and diminished catalyst
coverage.

Figure 4-12. Scanning electron microscopy characterization of nickel compound films on glassy
carbon electrodes before and after reductive cycling (0 to -0.8 V vs. RHE, 50 mV/sec) to peak
activity. All scale bars correspond to 50 μm. (A) shows GC-1 before reductive cycling. (B) shows
GC-2 before reductive cycling. (C) shows GC-3 before reductive cycling. (D) shows GC-1 after
300 cycles. (E) shows GC-2 after 200 cycles. (F) shows GC-3 after 1000 cycles.

Figure 4-13. Scanning electron microscopy image of GC-2 after reductive conditioning.
Image taken after reductive cycling (0 to -0.8 V vs. RHE, 50 mV/sec) to peak activity (200 cycles)
highlights the fusion of crystals after cycling. Scale bar corresponds to 10 μm.

75

The surfaces of GC-1 – GC-3 were further studied by Raman spectroscopy before
and after conditioning, Figure 4-14. The Raman spectra for GC-1 and GC-2 before
conditioning match those for powder samples of 2 and 28, respectively, confirming the
successful translation of the intact complex to the GC surface. Following conditioning, the
Raman spectra of GC-1 and GC-2 retain peaks associated with 2 and 28 clearly
demonstrating the complexes remain on the surface. In contrast, for GC-3 before
conditioning show intense Raman signals corresponding to the D, G, and G’ bands of
glassy carbon in addition to peaks associated with powder samples of 29. Following the
reductive conditioning, the peaks associated with 29, such as the band at 1500 cm-1, are
absent and only peaks associated with glassy carbon are observed.
This is attributed to poor initial coverage of the GC surface with substantial
loss of catalyst upon reduction. The desorption of 29 is supported by the similar
electrochemical activities of GC-3 following conditioning and bare GCE, Figure 4-15.
Electrochemical impedance spectroscopy (EIS) was used to study the effect of conditioning
on the electrical properties of the modified electrode surface. The impedance data was
interpreted using an equivalent circuit model, Figure 4-16, consisting of the resistance of
solution and wires (Rs) in series with an interfacial constant phase element (CPE) and a
charge transfer resistance (Rc) circuit in parallel along with a Warburg element (W). The
CPE is a circuit element used to replace a capacitor and is generally associated with a nonhomogeneous surface and variable current density at the electrode. The impedance of the
CPE is defined as:
ZCPE = 1(jω)−n /𝑄
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where Q is the magnitude of the CPE, j is the imaginary unit, ω is the angular frequency,
and n is the CPE exponent. The Warburg element was introduced to account for diffusion
resistance within crystalline domains, which are dominant prior to reductive cycling.
Details are reported in the appendix, Table A1.

Figure 4-14. Raman spectra of 2, 28 – 29 and GC1 – GC3 before and after conditioning. Spectra
were taken before and after reductive cycling (0 to -0.8 V vs. RHE, 50 mV/sec) to peak activity
and nickel compound powders on glass slides. (A) shows powdered 2 (purple trace), GC-1 before
cycling (green trace) and GC-1 after cycling (black trace). (B) shows powdered 28 (purple trace),
GC-2 before cycling (green trace), and GC-2 after cycling (red trace). (C) shows powdered 29
(purple trace), GC-3 before cycling (green trace), and GC-3 after cycling (blue trace).
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Figure 4-15. Polarization curves for bare glassy carbon (black trace) GC-3 prior to conditioning
(green trace) and GC-3 after conditioning (purple trace).

Figure 4-16. Equivalent circuit model used to fit EIS data.

Prior to conditioning, the Nyquist plots for GC-1 – GC-3 (Figure A36-A38) show
large charge-transfer resistance (Rc) values. The resistance for GC-3, 34,500 Ω, is larger
than GC-1, 25,100 Ω, and GC-2, 18,800 Ω. Following conditioning of 300 and 200 cycles,
respectively, the charge transfer resistance for GC-1 and GC-2 drop substantially to 270
and 160 Ω, respectively. This dramatic decrease indicates excellent charge transfer kinetics
between the film and electrode attributed to a reorganization of active sites to improve
contact with the electrode and solution. In contrast, GC-3 does not exhibit significant
change in charge transfer resistance upon conditioning and remains large, 34.0 kΩ.
Extended cycling to probe durability shows a slight increase in the charge transfer
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resistance for GC-1 and GC-2 to 370 and 420 Ω, respectively. This change is attributed to
a decrease in the number of active sites due to leaching and is consistent with the small
increase in overpotential.
The combined surface characterization techniques confirm morphological changes
of the catalyst coatings associated with a decrease in charge transfer resistance upon
exposure to reductive cycling. For GC-1 and GC-2, conditioning reorganizes the
microcrystalline domains as an open network arrangement which ostensibly allows for
greater solvent access and ion permeability. For GC-3, the initial catalyst film shows poor
electrode coverage and reductive cycling results in significant loss of catalyst by
delamination.
4.3 Conclusions
The immobilization of active homogeneous HER catalysts on electrode surfaces
has garnered recent attention. A fundamental aspect of these studies is the ability to
translate homogeneous solution phase activity to heterogeneous systems supported on an
electrode. In homogeneous systems, the HER activity is largely dependent on the electronic
structure of the catalyst, which dictates reduction potential and interactions with charged
substrate. The physical structure can also be important as demonstrated in catalysts with
pendant amines that help orient substrate for reduction. However, in heterogeneous systems
derived from small molecule catalysts the physical structure is an essential component as
it relates to catalyst-electrode interactions and charge transfer between electrode, catalyst,
and substrate.
The impact of small physical changes in electronically similar HER catalysts on the
ability to translate activity from homogeneous to heterogeneous solution has been
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demonstrated from the evaluation of 2, 28, and 29. A remarkable feature of this NiBTSC
system is the good stability of the surface adhered catalysts without inclusion of covalent
linkers to the surface. The non-covalent interactions between the catalyst and the electrode
allow dynamic reorganization upon reductive cycling, Scheme 4-2. Complexes 2 and 28
are rigorously planar with the strong stacking interactions observed in single crystals, while
the introduction of a –CH2CF3 side chain disrupts stacking interactions in the solid state of
29. The strong stacking interactions in 2 and 28 lead strong interaction between GC and
the catalyst and films dominated by microcrystal domains. Upon reductive cycling, these
domains reorganize with increased surface area and improved contact between electrode
and solution. In contrast, the absence of stacking ability for 29 leads to poor initial electrode
coverage and delamination upon reductive cycling. The results underscore the importance
of physical, solid state structure for the translation of homogeneous catalysts to solid
support and demonstrate how packing interactions in the crystal structure can be used to
help discriminate between catalysts with similar electronic structures.

Scheme 4-2. Conditioning via reductive cycling.
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CHAPTER V
SYNTHESIS, CHARACTERIZATION, AND BIOLOGICAL ACTIVITY OF NOVEL
ASYMMETRIC BIS-THIOSEMICARBAZONE DERIVATIVES
5.1 Introduction
The treatment of cancer has included surgery,153-156 hormone therapy,157-160
radiation,161-164 immunotherapy,165-169 and chemotherapy.170-173 Each of these treatments
come with side effects, with the most troublesome being the lack of selectivity between
cancerous and healthy cells. The drive to develop a cancer therapeutic that discriminates
in its apoptotic inducing behavior, has led to a new approach of targeted therapy. A
prominent targeted therapy is the use of monoclonal antibodies;174-178 however, even this
is not without side effects. Recently, the bis-thiosemicarbazone family of copper
complexes has been garnering attention for potential biological applications with minimal
side effects.38
The two most prominent bis-thiosemicarbazone complexes are 1 and CuGTSM.
Both have been evaluated for in vivo applications with 1 seeing more use as a diagnostic
tool for hypoxia imaging27-31 and CuGTSM as a therapeutic.38 The key difference of these
two complexes lies in their backbone, which ultimately effects their CuII/I reduction
potential with CuGTSM being 160 mV more anodic.38 The ability to tune the reduction
potential of these compounds allows for the exploitation of the different redox
environments of cancer cells in contrast to healthy cells. Radiolabeled 64Cu- and 62Cu-

81

ATSM have been shown to selectively remain in hypoxic tumor cells for improved
imaging. The ease of modular synthesis had led to a variety of BTSC complexes being
synthesized.7,13,15-18,20-21,40 A prime example of this is the modification of the ligand
framework to incorporate a small peptide sequence to enhance imaging. This synthetic
methodology could be employed to enhance cell type specificity and uptake with the
correct amino acid sequence.33 Further, Que and co-workers designed a novel imaging
agent that eliminates the employment of radiolabeled copper and makes use of

19

F MRI

imaging.32
The exploitation of CuGTSMs more anodic CuII/I couple as a cancer therapeutic
has led to an increase in studies on BTSCs and anti-cancer applications.11 Recently the
development

of

cyclized

derivatives,

the

condensation

of

4-methyl-4-

phenylthiosemicarbazide with glyoxal, were evaluated.39 Interestingly, these compounds
revealed a structure-activity relationship that suggested the mechanism of activity
involving DNA strand breaking. Expanding upon the structure activity relationship
revealed by the 4-methyl-4-phenylthiosemicarbazide derivatives,39 Palma et al. showed
that cytotoxicity could be increased with incorporation of cyclic amines even in Cu BTSCs
with similar CuII/I potentials to those observed for 1.63 Further, removing the hydrogenbond donor ability of the pendant amine group has been shown to increase efficacy by
preventing the system from being a substrate for MDR-1.65
All of these routes to improve the activity of 1 stem from modification of the
pendant amine functional group. The recently synthesized alkoxy CuATSM derivatives
10-15 (Chapter 3) established that the structural components remained identical to the 1
while the electrochemical properties were changed. This chapter reports the synthesis,
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characterization, and electrocatalytic behavior of a series of hybrid M(II) (where M = Ni,
Cu, and Zn) complexes derived from BTSCs, Scheme 5-1, for evaluation of anti-cancer
properties. The ligands are obtained in high yields using readily available, inexpensive
organic reagents according to literature methods. The resulting compounds have been
characterized by NMR, FT-IR, and UV-vis spectroscopies, x-ray crystallography (18, 19,
21, and 22), and cyclic voltammetry.

Scheme 5-1. Synthesis and numbering of ligand and metal chelates.

5.2 Results
5.2.1 Synthesis and Characterization
A series of hybrid ligands (16 – 18) with variation in the alkoxy alkyl chain length
of ethyl (16) and propyl (17) as well as incorporation of a phenyl group in the backbone
(18). The ligands were complexed with the metals Cu(II) (19 – 21), Ni(II) (22 – 24), and
Zn(II) (25 – 27). The ligands are obtained from bulk commodity chemicals. The synthetic
83

routes involves those previously described in Chapter 3 for the hydrazinecarbothioc acid
O-ethyl ester, and slight modification from previous literature reports for the mono-ketothiosemicarbazide. Briefly, dropwise addition of dilute 4-methyl-3-thiosemicarbazide to a
concentrated dione solution with rapid stirring results in the mono-condensed product that
is isolated via filtration. This can then be condensed with the hydrazinecarbothioc acid Oethyl ester to yield the full ligand as depicted in Scheme 5-1.
The 1H NMR of 16, Figure 5-1, displays a combination of prototypical chemical
shifts associated with BTSCs and the alkoxy ligands (4 – 9). Whereas the molecule is
asymmetric, the backbone protons remain in similar magnetic environments and occur as
a single peak at 2.17 ppm. The methyl protons from the pendant amine are observed as
singlet at 3.00 ppm, while the methyl protons from the alkoxide moiety yield a singlet
upfield at 1.28 ppm. The pendant amine proton is observed at 8.35 ppm, the iminio proton
of the thiosemicarbazide side is at 10.21 ppm, and the imino proton of the alkoxide side
displays the two chemical shifts of 11.31 ppm and 11.62 ppm (Chapter 3). The 13C NMR
of 16, Figure 5-2, exhibits the chemical shift for the alkoxy carbon at 66.3. The alkyl peaks
of the backbone carbons, –NHCH3, and CH3 from the ethyl alkoxide are observed in the
peaks at δ 11.8 – 31.7. The C=N is present at 179.0 and the C=S at 152.5 and 147.9
respectively. The 1H and

13

C NMR of 17 and 18 are similar and can be found in the

Appendix (Figures A40-A43).
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Figure 5-1. 1H NMR of 16 in DMSO.

Figure 5-2. 13C NMR of 16 in DMSO. Inset shows DMSO peak.

The FT-IR of 16 (Figure 5-3) is representative of the class of ligands with the
remaining found in Appendix (Figures A44-A45). Notably, 16 displays a combination of
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hallmark stretches of both BTSCs, two N–H stretches at 3382 and 3253 cm-1, and the
previously synthesized alkoxy ligands, C–O at 1130 cm-1. Upon metalation with copper
(19), Figure 5-3 B, the N–H stretch present at 3382 cm-1 is absent consistent with
deprotonation of the imino hydrogen. However, an N–H stretch is observed at 3305 cm-1
due to the presence of the pendant amine. The C–O stretch remains largely unaffected at
1132 cm-1. Further, the addition of stretches at 846 and 782 cm-1are attributed to C–S and
Cu–N bonds respectively. Similar stretches, such as the appearance of Ni–S/Ni–N and Zn–
S/Zn–N are observed in the remaining FT-IR spectra and can be found in the Appendix
(Figures A46 – A51).

Figure 5-3. FT-IR of 16 (A) and 19 (B) as powders.

When 16 is chelated with zinc (25) the 1H NMR (Figure 5-4) displays full
deprotonation of the imino hydrogens with the absence of a peaks at 10.21 and 11.31/11.62
ppm. This trend is consistent with the remaining zinc complexes (Figures A52-56). The
nickel derivatives display a similar 1H NMR pattern, however in all nickel complexes a
peak at 8.55 is present (Figures A57-A59). This is not attributed to the imino hydrogens as
those are over 2 ppm downfield, and in the FT-IR (Figure 5-5) of 22 there is only one N–
H stretch. This peak is attributed to a small amount of residual acetic acid.
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Figure 5-4. 1H NMR of 25 in DMSO.

Figure 5-5. FT-IR of 22 as a powder.
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The electronic spectra of 19 – 27 were collected in acetonitrile, and all display two
ligand to ligand charge transfer bands and one metal to ligand charge transfer band. The
electronic spectra of the Cu complexes (19 – 21) are displayed in Figure 5-6. Compounds
19 and 20 contain ligand to metal charge transfer bands at 477 and 473 nm respectively.
The charge transfer band in 21 is redshifted by 346 cm-1 (8 nm) to 485 nm relative to 19.
This redshift is observed within the higher energy ligand to ligand charge transfer values.
The recorded ligand to ligand charge transfer band for 19 and 20 are observed at 248 and
249 nm. For 21 this value is red shifted by 2,300 cm-1 relative to 19, to 263 nm.
Interestingly, the lower energy band remains consistent in all complexes at a value of 309
nm. The remaining electronic spectra of Ni (22 – 24) and Zn (25 – 27) can be found in the
Appendix (Figures A60-A61). In both of these systems the redshift is observed for the
phenyl derivative, 24 for the Ni and 27 for the Zn. In the Ni system, however, the high
energy ligand to ligand charge transfer band remains similar with all occurring around 255
nm. The lower energy band however has values of 329 and 330 nm for 22 and 23
respectively, whereas 24 appears at 342 nm, a redshift of 1156 cm-1. Lastly, in the Zn
complexes, all charge transfer bands of 27 are redshifted relative to 25 and 26. The ligand
to ligand charge transfer bands are observed at 243 and 299 nm for 25 and the metal to
ligand charge transfer occurring at 422 nm. However, in 27 the corresponding transfer
bands occur at 269, 326, and 430 nm, redshift values of 3,978 cm-1, 2,770 cm-1, and 441
cm-1.
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Figure 5-6. UV-visible spectra of 19 (blue trace), 20 (red trace), and 21 (black trace) recorded in
acetonitrile.

5.2.1 HER Catalysis Evaluation
We had previously established that 1, 3, and its ligand,10,34 are viable for proton
reduction catalysts. As described in Chapter 3, substitution of the –NHMe groups of 1 with
the –OMe of 10 results in a large anodic shift in the reduction potential. Such a shift could
potentially lower the overpotential of these types of HER catalysts. To this end 10 was
evaluated as a possible HER catalyst, but ultimately failed. The absence of HER activity
was attributed to the first step of the mechanism of HER evolution of CuATSM,
protonation. A ligand framework with electron withdrawing groups (EWG) can lower
reduction potentials. However, the employment of these EWGs leads to a loss of basicity
in the ligand framework. To rectify this situation, a hybrid ligand was developed in which
one pendant group was –NHMe and one was –OEt. The complex was further modified by
incorporation of a phenyl group in the backbone, 21. Under catalytic conditions 21 (blue
trace), was found to produce hydrogen unlike 10 (red trace), Figure 5-7. Ultimately though
21 did not produce H2 at a reasonable overpotential. To investigate this, spectrophotometric
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titrations were employed. CuATSM was used as the standard since at this point it was the
best performing CuBTSC HER catalyst.

Figure 5-7. Comparison of 21 and 10 under catalytic HER conditions.

The dissolution of 1 in DMSO gave a red solution which then had its UV-vis
recorded, Figure 5-8 top, black trace. Then triflic acid was added in sequential 30 μL
aliquots, with spectrums recorded after each addition, Figure 5-8 (for clarity, only select
total additions are shown). During the course of the titration a color change was observed
from red to yellow, as indicated in the blue shift of the λmax from 480 to 460 nm. To ensure
that the endpoint was reached, the corrected absorbance of 480 and 460 nm vs acid addition
was plotted until a plateau was achieved, Figure 5-8 bottom.
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Figure 5-8. Selected UV-Vis spectra of 1 during titration (top) Corrected absorbance vs additions
of acid for 480 and 460 nm (bottom).

This same experiment was perfomred for 21, Figure 5-9. As previously seen with
1, there is a blue shift in the λmax, from 490 to 450 nm and an isobestic point is observed at
460 nm. These observations lead to the conclusion that restoration of the amine moiety
allowed for protonation. However, it is important to note the volume of acid requisite to
reach the saturation point of 21 of 660 μL compared to that of 1 of 420 μL. This increase
in acid addition is attributed again to the EWG of the alkoxy moiety leading to a decrease
in overall basicity of the complex.
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Figure 5-9. Selected UV-Vis spectra of 21 during titration (top) Corrected absorbance vs
additions of acid for 490 and 450 nm (bottom).

Work done by Jain et al.76 and others35 highlighted the potential for NiBTSC
complexes as homogeneous HER catalysts. Notably, the first step in the HER mechanism
of NiBTSCs is reduction, not protonation. This change in mechanism could potentially
allow for the employment of stronger EWG’s without shutting down catalysis due to lack
of basicity. These results lead to the use of NiATSM (2) as a parent compound, and
synthesize 28 and 29 to investigate the effect of EWGs and electron donating groups (EDG)
on heterogeneous HER catalysis, as described in Chapter 4.
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5.2.1 Crystallography
The solid state structures of 18, 19, 21, and 22 were determined by single crystal xray diffraction. The copper complexes 19 and 21 crystallized as a dark orange needle and
an orange plate, respectively, in the space group P-1. The nickel complex 22 crystalized as
an orange plate in the space group P21/c. The ligand, 18, crystallized as a yellow prism in
the space group P21/c. All four complexes crystallize without inclusion of solvent
molecules. Crystallographic data and structural refinement details are listed in the Chapter
2 Tables 2-3 to 2-4.
The ORTEP95 representations of 18, 19, 21, and 22, Figure 5-10 (A-D), show that
each metal lays in a square planar N2S2 donor environment. Selected bond distances and
angles can be found in Table 5-1. The Ni–N and Ni–S bonds are different from that of the
Cu–N and Cu–S bonds, with the former having the shorter bond lengths. However, within
a metal class, the chelation bonds are not statistically different. The Cu–N bond distances
of 1.959(2) and 1.967(2) for 19 are not different from those of CuATSM96 with
corresponding lengths of 1.9584(16). This is also in good agreement with the Cu(II)
compounds reported in Chapter 3.82 The Cu-S bonds, of 2.2529(7) and 2.2795(7) for 21,
and 2.2453(5) for that of CuATSM are also statistically equivalent. The same structural
trend is observed for the Ni(II) complexes with the Ni–N and Ni–S bond lengths for all
compounds. Within the ligand framework, all bond distances across the series regardless
of the chelated metal are statistically equivalent. They are consistent with a conjugated πsystem of alternating single and double bonds. The bond distances in 19 of S1–C5, N1–
N2, and C1–C2, are 1.761(3), 1.362(3), and 1.477(3) Å, respectively, which are typical of
single C–S, N–N, and C–C bonds. The remaining ligand framework bonds N1–C1 and N2–
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C5 are shorter with distances of 1.293(3) and 1.318(3) Å respectively, consistent with C=N
bond character. The sum of the four bond angles about the Cu is 358.33(0.12) °.

Figure 5-10. ORTEP95 representations of 18(A), 19 (B), 21 (C), and 22 (D).

All three chelates are rigorously planar. For complex 22, the best fit plane of all 18
non-hydrogen atoms has a standard deviation of ±0.128 Å with the largest deviation being
±0.326 Å for C9. For 19, the best fit plane for all 18 non-hydrogen atoms has a standard
deviation of ±0.067 Å with the largest deviation of ±0.116 Å for C9. Excluding the phenyl
ring in 21 (C5-C9) the best fit plane for all 18 non- hydrogen atoms has a standard deviation
of ±0.137 Å with the largest deviation of ±0.329 Å for C12 (C7). The phenyl ring atoms of
C5-C9 are planar within the ring, with a standard deviation of ±0.013 Å with the largest
deviation of ±0.01662 Å for C5. The phenyl ring within the free ligand exhibits the same
phenomenon with a standard deviation of ±0.013 Å and with the largest deviation of
±0.01662 Å for C5.
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Table 5-1. Selected bond distances and angles for 18, 19, 21, and 22.
Bond Distance 18
19
21
22
M–N1
N/A
1.967(2)
1.9755(14)
1.868(3)
M–N3
N/A
1.959(2)
1.9590(13)
1.859(2)
M–S1
N/A
2.2529(7)
2.2725(4)
2.1554(8)
M–S2
N/A
2.2795(7)
2.2871(5)
2.1740(8)
S1–C5 (C10)a
1.6736(13)
1.761(3)
1.7584(17)
1.760(3)
S2–C6 (C11)a
1.6568(14)
1.758(3)
1.7376(16)
1.753(3)
a
O1–C6 (C11)
1.3160(13)
1.332(3)
1.3339(19)
1.334(4)
N1–C1
1.2898(17)
1.293(3)
1.298(2)
1.303(4)
N1–N2
1.3660(15)
1.362(3)
1.3611(19)
1.376(4)
N2–C5 (C10)a
1.3672(17)
1.318(3)
1.319(2)
1.319(4)
a
N5–C5(C10)
1.3251(18)
1.338(3)
1.331(2)
1.338(4)
C1–C2
1.4778(18)
1.477(3)
1.472(2)
1.473(4)
C1–C3
1.496(2)
1.492(4)
1.492(2)
1.488(4)
Bond Angles
N3–M–N1
N/A
80.31(9)
79.68(6)
83.38(11)
N1–M–S1
N/A
84.58(6)
83.31(4)
87.18(8)
N3–M–S2
N/A
84.59(6)
84.49(4)
87.27(8)
S1–M–S2
N/A
108.85(3)
111.359(16) 102.15(3)
a) Numbers are different due to presence of benzene rings in 18 and 21.
5.2.2 Electrochemistry
The importance of electrochemical properties of the BTSC complexes has been
well documented. The cyclic voltammograms of the free ligands and metal chelates can be
found in Figure 5-11 (A-D). Notably, both the Cu and Ni derivatives display quasireversible events in their respective voltammograms. This is in contrast to the Zn and free
ligand voltammograms, which display two irreversible reductions. As the chelated metal
is varied, a periodic trend is observed with Cu have the most anodic events, followed by
Ni, then Zn, and lastly the free ligand. The CuII/I couple is 0.57 - 0.63 V more anodic than
that of the first redox event of the Ni class (ligand centered) and 1.28 - 1.36 V more anodic
than the Ni II/I couple, Table 5-2. The Ni ligand centered reduction is 0.41 – 0.42 V more
anodic than that of the first Zn reduction and 0.55 - 0.68 V than the first free ligand
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reduction. Lastly the Zn stabilizes the ligand centered reductions by 0.14 - 0.26 V and 0.47
- 0.56 V more anodic than the respective free ligand events.

Figure 5-11. Cyclic voltammograms over lays of ligand framework 16 (red trace) and 18 (blue
trace) with their respective chelates copper (A), nickel (B), zinc (C) and, free ligand (D).

Across the ligand series, there is a clear effect of electron donor ability from the R
groups on reduction potential. The alkyl extension of R2 from ethyl to propyl resulted in a
minimal or no effect on reduction potential.82 This is exemplified in the 0.01 V shifts for
Cu complexes 19 and 20, and first free ligand reduction, 16 and 17, event and the 0.03 V
shift for the second Zn reduction in 25 and 26. All other redox couples were unchanged by
alkyl extension. However, the incorporation of a phenyl group in R1 caused a significant
anodic shift in reduction potential for all compounds. For the Cu complexes 19 and 21, a
0.08 V anodic shift is observed. The most dramatic effect on the reduction potential is for
the free ligand 16 and 18, which exhibited a 0.17 V anodic shift in potential.
In comparison with the previously reported ATSM and GTSM the copper
derivatives are found to lay more anodic than both, with potentials of -1.11 and -0.950 V
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respectively. This indicates that these compounds could have potential use in anti-cancer
applications given the accessibility of their reduction potentials. This clearly demonstrates
the ability to tune the reduction potential via the incorporation of an alkoxy moiety on only
one side of the ligand framework cause the potential to lay in between that of the bis-amine
and bis-alkoxy derivatives.
Table 5-2. E1/2 values for 16-27 (V) vs Fc+/Fc
Ligand
Cu(II/I)
NiL/NiLNi(II/I)
-0.930
-1.56
-2.21
16
-0.940
-1.56
-2.22
17
-0.850
-1.42
-2.12
18

ZnL/ZnL-1.98
-1.98
-1.83

ZnL-/ZnL2-2.37
-2.40
-2.22

L/L-2.23
-2.24
-1.97

L-/L2-2.70
-2.70
-2.53

5.2.3 Cell line Evaluation
To investigate any potential therapeutic effects the compounds may have for anticancer, they were screened against the cancer cell line A549 and its healthy counterpart
IMR-90. This work was conducted in collaboration with Dr. Paula Bates at the University
of Louisville Medical School. All MTT assay experiments were performed by Dr. Sarah
Andres. The MTT assay of ligand system 16, 17, and 18 are shown in Figure 5-12 and 513 (A and B), respectively. Since all compounds display redox activity, redox activity alone
does not lead to enhanced therapeutic potential. The Cu complexes 19, 20, and 21 have
respective GI50 values of 0.082, 0.29, and 0.065 μM for A549, compared to >2.0, >2.0,
and 1.3 μM of the IMR-90 cells line, Table 5-3. The nickel derivatives, 22, 23, and 24,
display larger GI50 values for both A549 and IMR90 cell lines, with no clear trend in
selectivity. The difference in performance for the Cu and Ni complexes is attributed to the
relatively accessible reduction potential of the Cu complexes as compared to Ni, Table 52. With the copper chelates displaying substantially more anodic potentials, the Cu(II) core
of 19 – 20 are capable of being reduced to Cu(I) intracellularly and thus have high
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bioactivity. This selectivity trend based on reduction potential not only explains the
difference between our copper and nickel compounds but also previously reported ATSM
derivatives, appendix Figure A62. It is clear that when both cell types are treated with
CuATSM, a larger dose is required to see the anti-proliferation effects with the A549 and
IMR90 cells. This result shows that even with the same chelated metal, Cu, the CuII/I
reduction potential is crucial in creating a selective therapeutic.
Table 5-3. GI50 values for 16-27.
Cu
Ni
Zn Ligand
Ligand/Cell line GI50 (μM)
16 A549
0.082 3.0
0.59
0.60
16 IMR90
>2.0
5.3
0.68
1.1
17 A549
0.29 10.1 0.45
0.47
17 IM90
>2
13
0.52
>2
18 A549
0.065 37 0.055 0.091
18 IMR90
1.3 >100 1.1
>2
To examine any potential trans-metallation and structural ligand effects
both the free ligand and Zn complexes were evaluated for their potential therapeutic
capabilities. It is evident from the MTT assays that the ligand framework can play a key
role in biological activity. The free ligands 16 and 17 and Zn complexes 25 and 26 show
lower therapeutic potential relative to their Cu analogues. The compounds 16, 17, 25, and
26 display improved therapeutic capabilities when they are compared to their
corresponding Ni analogues. This is not the case however, for the free ligand 18 and Zn
complex 27. The MTT assay profiles are nearly identical to their copper analog 21. This
degree of similarity could suggest potential trans-metallation is occurring in the growth
media and the copper complex is being generated in situ and is the active species. Should
this have been the case then both 25 and 26 would have displayed similar profiles to their
copper analogs, which they do not. Interestingly, all the free ligands 16 – 18 display similar
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profiles to their Zn complexes 25 – 27. Thus any difference in the activity of the ligands
and Zn compounds can be attributed to a structural effect. The major structural difference
of 18 compared to 16 and 17 is the presence of the phenyl group in the backbone. It should
be noted that 18, was not purified from the crude product, which may be contaminated with
starting material, so some activity could be from the unreacted starting material. It is also
possible that there was a difference in copper concentration in the culture media from the
different lots of media employed during screening, leading to more extensive
transmetallation in the evaluation of 18 and 27. To ensure all compounds are evaluated
under identical copper concentrations, the media needs to be scrubbed with
tetrathiomolybdate.
Interestingly, the phenyl structural component does not lead to activity in 24. The
lack of activity of 24 can be attributed to its d-electron count. Compounds 21, and 27 after
reduction, are d10 thus are kinetically labile however, even after reduction, 24 is only d9. In
the kinetically labile 21 and 27, the metal is proposed to dissociate leaving the active ligand
which has more conformation flexibility than the metal complexes. In 24 however, the
ligand framework is forced to remain in the square planar chelate system and thus is not
capable of achieving the required orientation for inhibition. An interesting possibility for
a mechanism of action is that the ligand is the biologically active material and the metal
plays the role of chaperone. If reduction potential was the dominant factor for potency,
then it would be expected that 21 would display substantially higher activity compared to
its more cathodic analogs 19 and 20. Given the similarity of their GI50 values, this is most
likely not the case. However, if bioactivity was predominantly based on structure, then the
nickel derivatives 22 – 24 would be as active. The ligand itself also does not display equal
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or better activity to the copper derivatives. This led to the hypothesis that the square planar
nature of the metal chelate enhances cellular uptake and the reduction potential then allows
for selectivity. After reduction in the desired cell, the metal can be released leaving the free
ligand to inhibit cellular respiration (Scheme 5-2).

Figure 5-12. MTT assay results of cell lines A549 (top) and IMR90 (bottom) for the free ligand
16 (black trace), Cu complex 19 (red trace), Ni complex 22 (green trace) and Zn complex 25
(blue trace).
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Figure 5-13. MTT assay results of cell lines A549 (top) and IMR90 (bottom) for the free ligands
17 (A) and 18 (B) (black trace), Cu complexes 20 (A) and 21 (B) (red trace), Ni complexes 23 (A)
and 24 (B) (green trace) and Zn complexes 26 (A) and 27 (B) (blue trace).

Scheme 5-2. Proposed mechanism of action for anti-cancer effects from copper chelates.
101

5.2.4 National Cancer Institute 60 Cell Line
Compounds 19 and 21 were sent to the NIH to be examined with the National
Cancer Institute 60 Cell Line (NCI-60) screening. The NCI-60 is a panel of a variety of
carcinogenic cell lines used to examine compounds for their anti-cancer properties.
Notably, the diversity of the carcinogenic cell lines employed allows for the comparison of
tested compounds against known anti-cancer agents to identify a possible mechanism of
action. The results, shown in Figure 5-14 and 5-15 respectively, show that these
compounds are active against most of the tested cell lines with similar profiles, and in most
cases were cytotoxic. It should be noted however that both compounds were completely
inactive against all leukemia lines. The stark contrast in activity may be attributed to the
difference in the types of cancer. The compounds were most active against cell lines
derived from solid tumors, whereas leukemia is not. The cell lines derived from solid
tumors may provide a more hypoxic environment that would allow the redox active
compounds to operate as anti-cancer agents, whereas a lack of a hypoxic environment, such
as in the leukemia cells, would prevent any cytotoxicity via redox active compounds. It
should be noted that the cell lines derived from solid tumors are not grown under a hypoxic
environment. Also, several tumor cell lines displayed resistance to our compounds. This
resistance has yet to be fully understood, but elucidation of their differences relative to the
rest of the solid tumors will provide valuable insight into the mode of action of these
compounds.
5.3 Conclusions
A new ligand system and the corresponding nickel, copper and, zinc chelates were
successfully synthesized. Incorporation of the alkoxy moiety allows tuning of the
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reduction potential to achieve values relevant for biological activity. Further, the effect of
structure on activity was demonstrated with the improved potency of the phenyl
derivative. The NCI-60 screening demonstrates that this new class of chelates are active
against a wide variety of cell lines however, a clear mechanism of action is yet to be
elucidated.

Figure 5-14. NCI-60 profile of 19 displaying the percent growth relative to the control.

103

Figure 5-15. NCI-60 profile of 21 displaying the percent growth relative to the control.
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CHAPTER VI
CONCLUSIONS
The progress of BTSC’s in therapeutics and diagnostics prompted the synthesis of
alkoxy analogues to explore a new functional group and its effect on structure and
reduction potentials. A total of six new ligands (4 – 9) and their copper chelates (10 – 15)
were synthesized from bulk commodity chemicals with decent yields. Importantly the
synthetic route uses alcohols, both primary and secondary alcohols for the starting material,
which enables a variety of derivatives to be synthesized. The investigation into the structure
revealed that all of the copper chelates (10 – 15) were analogous to CuATSM. Single
crystal X-ray crystallography showed that these chelates are rigorously planar, a crucial
facet to be capable of entering cells. Further the relative energy of the d-orbital manifold
was found to be similar. However, the electrochemistry revealed a substantial anodic shift
in the CuII/I potential of ~250 mV when comparing 10 to CuATSM. This large shift even
puts these systems more anodic than CuGTSM, which makes them interesting as possible
drug candidates. The observed shift allows for greater tuning of the electrochemistry of
these types of ligand frameworks, which has been shown to be important to the function of
the BTSC class. However, by removing the two hydrogen bond donors that are present in
the ATSM framework, the solubility was significantly altered. These alkoxy systems could
only be dissolved in halogenated organic solvents, like DCM, effectively neutralizing any
potential therapeutic properties that require dissolution prior to treatment. If a suspension
or oral gavage could be employed these systems can be evaluated for their drug like
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properties. It should be noted that the reduction potential of these systems is only
modulated within a three carbon chain length, meaning effectively the solubility could be
restored with a functionalized alcohol without effecting the redox couple. One possible
synthetic route that could be explored to implement these more exotic alcohols is transesterification much like Que and co-workers demonstration of the applicability of transamination. Further the alkoxy class of ligands failed to act as HER catalysts due to the poor
basicity of the ligand framework. This result demonstrated the limit of electron
withdrawing that future investigations could employ to attempt to minimize the
overpotential of such catalysts, a central step in rational design.
The data from the alkoxy systems (4 – 15) prompted the restoration of the pendant
amine on one side of the ligand to create a hybrid system. Notably, this improved solubility,
catalysis performance, and cathodically shifted the CuII/I potential relative to the alkoxy
functionality. Ultimately though, the hybrid system failed to perform adequately as an HER
catalyst. However, this again showed that while this system was capable of producing H2,
the electron withdrawing functional group prevents sufficient performance, leading to the
focus of improvement on traditional BTSC complexes.
Three Ni BTSCs were immobilized on a glassy carbon electrode for heterogeneous
HER catalysis. Catalysts 2 and 28 displayed similar HER performance, whereas 29, was
substantially different. This difference in performance is attributed to the solid state
intermolecular packing. Single crystal X-ray crystallography provided essential insight to
how the complexes interacted in the solid state. The two rigorously planar systems, 2 and
28 behaved and packed in nearly identical fashions with closer intermolecular contacts less
than 3.60 Å. The fluorinated groups of 29 prevented the molecules from forming close
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contacts with one another and the electrode surface. Thus inhibiting electron transport and
leading to larger overpotentials and charge transfer resistance. Whereas the planar
derivatives 2 and 28 can undergo dynamic re-arrangement during reductive cycling to form
a better contact to the electrode surface that improves overall performance. Raman
spectroscopy further revealed that 29 was lost from the electrode surface during reductive
cycling.
The significant improvement after conditioning is vital to further enhancing overall
catalyst performance of these systems. Both 2 and 28 display remarkable stability on the
electrode surface and retained activity after extended cycling. The remarkable longevity
without a covalent linker is crucial in development of these systems as the dynamic
rearrangement is necessary for catalyst improvement and would be impossible if covalently
linked to the electrode surface. A potential improvement could be made by incorporation
of a molecule that facilitates electron transfer to further lower the charge transfer resistance
for 2 and 28. For 29, the poor packing and lack of stability prevented an adequate analysis
of electron withdrawing groups on heterogeneous catalysis for NiBTSCs. Thus synthesis
of a novel derivative that can form close contacts and longevity on the electrode surface as
displayed by 2 and 28, is paramount to further catalyst development.
The hybrid system failed for HER catalysis but the anodically shifted Cu II/I
reduction potential and improved solubility due to restoration of the hydrogen bond donor
amine, indicated potential anti-cancer properties. A series of ligands (16 – 18) were
synthesized and chelated with metals Cu (19 – 21), Ni (22 – 24), and Zn (25 – 27) to give
a total of 12 new compounds, which were each screened for therapeutic potential via an
MTT assay. The results of the MTT assay point to the copper derivative being the most
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potent and selective between carcinogenic cells and healthy. Interestingly these results
show that while reduction potential is crucial for activity and selectivity, there is an
emerging importance of structure. The more active systems of the copper, zinc, and free
ligand are deemed capable of becoming the free ligand (or are already) when in the cell.
The copper system is capable of being reduced to Cu(I) which is kinetically labile, like
zinc. Notably, the reduction potential of the zinc system is not capable of being achieved
intracellularly, meaning the activity observed from zinc is purely structural. The same
argument however does translate to the nickel derivative. The exception is that even if
reduction was achieved for the nickel system, it would still be kinetically inert, so only
structural effects of the chelate are observed. This explains why the zinc and free ligand
have such similar profiles and the nickel performs poorly. Further, this explains the
enhanced selectivity and potency of the copper complexes. The chelated form allows for
facile diffusion across membranes, and the copper is only released when reduced.
Additionally, if the reduction potential was the dominant factor in effectiveness, then 21
should show a significant increase in performance relative to 19. Although 21 does display
a minor decrease in concentration required to achieve a GI 50, it is minimal considering
the larger anodic shift. Additionally, 19 and 21 were screened against the 60 cell lines in
the NCI 60 assay. Both systems exhibited a similar profile with high activity and
cytotoxicity against a wide variety of cell lines derived from solid tumors. The leukemia
cell lines remained unaffected by these complexes, providing valuable insight that can help
elucidate a clear mechanism. These results are the first to demonstrate that the structure of
the ligand and the CuII/I redox couple together lead to selectivity and activity. This will
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allow for better design of new systems to exploit the metal as the chaperone, but tuning the
ligand to act as the drug.
Further, it has been demonstrated in the literature that BTSCs are substrates for
MDR-1 due to their hydrogen bond donor pendant amine. It is plausible that tuning the
reduction potential with the alkoxy functionality led to enhanced potency of these systems
via inhibiting specificity for MDR-1. A binding affinity assay comparing ATSM to the
hybrid could prove this, and thus further render the previous alkoxy complexes, 10 – 15
desirable for therapeutics with lack of hydrogen bond donors and more anodic Cu II/I
potentials. However, solubility needs to be increased without restoration of hydrogen bond
donors so as not to make the modified system a substrate for MDR-1.
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APPENDIX

Figure A1. H2ETCB (5) 1H NMR
(C2D6NO, 400 MHz) δ 1.51 (br, 6H) 2.46 (br, 4H) 4.74 (s, 6H) 11.51 (s, 1H) 11.92 (s,
1H).
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Figure A2. H2PTCB (6) 1H NMR
(CDCl3, 400 MHz) δ 0.99 (t, 6H, J=7.28) 1.84 (quin, 4H, J=6.24) 2.13 (s, 6H) 4.55 (t,
4H, J=6.22) 9.15 (s, 2H).
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Figure A3. H2PTCB (6) 13C NMR
(CDCl3, 100 MHz) δ 9.78, 10.3, 21.9, 29.7, 187.6
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Figure A4. H2iPTCB (7) 1H NMR
(CDCl3, 400 MHz) δ 1.41 (br, 12H) 2.12 (s, 6H) 5.63 (br, 2H) 9.10 (s, 2H).
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Figure A5. H2iPTCB (7) 13C NMR
(CDCl3, 100 MHz) δ 9.9, 21.6, 148.3, 186.7.
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Figure A6. H2OTCB (8) 1H NMR
(CDCl3, 400 MHz) δ 0.87 (br, 6H) 1.28 (m, 16H) 1.43 (br, 4H) 1.81 (br, 4H) 2.13 (s, 6H)
4.59 (br, 4H) 9.12 (s, 2H).
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Figure A7. H2OTCB (8) 13C NMR
(CDCl3, 100 MHz) δ 14.1, 22.6, 25.8, 28.4, 29.1, 31.7.
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Figure A8. H2ETCH (9) 1H NMR
(CDCl3, 400 MHz) δ 1.08 (br, 6H) 1.41 (br, 6H) 2.63 (br, 4H) 4.63 (br, 4H) 9.23 (br, 2H).
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Figure A9. H2ETCH (9) 13C NMR
(CDCl3,100 MHz) δ 10.49, 14.02, 17.01, 68.87, 152.27, 187.47.
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Figure A10: FT-IR of H2ETCB (5)
Infrared spectrum of the H2ETCB ligand as a powder (ATR)

Figure A11: FT-IR of H2PTCB (6)
Infrared spectrum of the H2PTCB ligand as a powder (ATR)
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Figure A12: FT-IR of H2iPTCB (7)
Infrared spectrum of the H2iPTCB ligand as a powder (ATR)

Figure A13: FT-IR of H2OTCB (8)
Infrared spectrum of the H2OTCB ligand as a powder (ATR)
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Figure A14: FT-IR of H2ETCH (9)
Infrared spectrum of the H2ETCH ligand as a powder (ATR)

Figure A15: FT-IR of Cu(ETCB) (11)
Infrared spectrum of the Cu(ETCB) ligand as a powder (ATR)
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Figure A16: IR Spectrum of Cu(PTCB) (12)
Infrared spectrum of Cu(PTCB) as a powder (ATR)

Figure A17: IR Spectrum of Cu(iPTCB) (13)
Infrared spectrum of Cu(iPTCB) as a powder (ATR)
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Figure A18: IR Spectrum of Cu(OTCB) (14)
Infrared spectrum of Cu(OTCB) as a powder (ATR)

Figure A19: IR Spectrum of Cu(ETCH) (15)
Infrared spectrum of Cu(ETCH) as a powder (ATR)
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Figure A20. Cu(ETCB) (11) UV-Vis in dichloromethane

Figure A21. Cu(PTCB) (12) UV-Vis in dichloromethane
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Figure A22. Cu(iPTCB) (13) UV-Vis in dichloromethane

Figure A23. Cu(OTCB) (14) UV-Vis in dichloromethane
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Figure A24. Cu(ETCH) (15) UV-Vis in dichloromethane

Figure A25. Cu(MTCB) (10) EPR on powder at room temperature
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Figure A26. Cu(ETCB) (11) EPR on powder at room temperature

Figure A27. Cu(iPTCB) (13) EPR on powder at room temperature
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Figure A28. Cu(OTCB) (14) EPR on powder at room temperature

Figure A29. Cu(ETCH) (15) EPR on powder at room temperature
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Figure A30. Cyclic voltammogram of 11 in DCM at 200 mV/s

Figure A31. Cyclic voltammogram of 12 in DCM at 200 mV/s
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Figure A32. Cyclic voltammogram of 13 in DCM at 200 mV/s

Figure A33. Cyclic voltammogram of 14 in DCM at 200 mV/s
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Figure A34. Cyclic voltammogram of 15 in DCM at 200 mV/s

Figure A35. FTIR of 28 as a powder (ATR)
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Table A3. Parameters obtained by fitting frequency response analysis (FRA) data to
simulated RCW circuit
Zview software179 was used to fit data. Q is the magnitude of the CPE, Rc is the charge
transfer resistance, Rs is approximate solution resistance, n is the CPE exponent, and C is
the capacitance. Capacitance values were calculated using 𝐶 = 𝑅𝑐
GC
#
Cycle
s
Q (F
sn-1)
Rc
(Ω)
Rs
(Ω)
N
C (F)
χ2

1−𝑛
𝑛

1

∗ 𝑄 𝑛 .180-184

1
0

300

1000

2
0

200

1000

3
0

1000

1500

2.43E6
25099

4.52E6
270

4.46E6
374

2.63E6
18843

6.10E6
158

6.33E6
374

2.24E6
34518

1.75E6
34049

1.73E6
45793

26.22

20.12

17.99

16.80

15.09

13.9

7.24

5.37

5.78

0.908
1.83E6
0.0001
5

0.929
2.71E6
0.0012
1

0.913
2.43E6
0.0014
1

0.916
2.00E6
0.0007
2

0.893
2.65E6
0.0005
7

0.864
2.49E6
0.0005
7

0.893
1.65E6
0.0003
0

0.899
1.27E6
0.0031
3

0.896
1.29E6
0.0025
2

Figure A36. Nyquist plots showing the effects of reductive cycling from 0 to -0.8 V vs.
RHE at 50 mV/sec on the impedance of GC-1.
Solid traces represent fitted impedance data, while dotted traces represent actual data. (A)
Nyquist plot showing impedance at 0 cycles (before any reductive cycling) and after 300
cycles (peak activity, in small frame). (B) The same data as in (A), but with axes scaled
down to show impedance after 300 cycles in greater detail. (C) Comparison of Nyquist
plots for GC-1 after 300 cycles and 1000 cycles.
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Figure A37. Nyquist plots showing the effects of reductive cycling from 0 to -0.8 V vs.
RHE at 50 mV/sec on the impedance of GC-2.
Solid traces represent fitted impedance data, while dotted traces represent actual data. (A)
Nyquist plot showing impedance at 0 cycles (before any reductive cycling) and after 200
cycles (peak activity, in small frame). (B) The same data as in (A), but with axes scaled
down to show impedance after 200 cycles in greater detail. (C) Comparison of Nyquist
plots for GC-2 after 200 and 1000 cycles.

Figure A38. Nyquist plots showing the effects of cycling from 0 to -0.8 V vs. RHE at 50
mV/sec on the impedance of GC-3.
Solid traces represent fitted impedance data, while dotted traces represent actual data. (A)
Comparison of Nyquist plots for GC-3 at 0 cycles (before any reductive cycling) and
after 1000 cycles. (B) Comparison of Nyquist plots for GC-3 after 1000 and 1500 cycles.
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Figure A39. Tafel slope as a function of number of cycles for each modified glassy
carbon electrode.

Figure A40. 1H NMR (400 MHz) of 17 in DMSO-D6.
δ 0.94 (br, 3H) 1.70 (br, 2H), 2.11 and 2.19 (s/br, 6H) 3.00 (s, 3H) 4.41 (br, 2H) 8.43
(s,1H) 10.25 (s, 1H) 11.35 and 11.63 (s, 1H)
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Figure A41. 13C NMR (100 MHz) of 17 in DMSO-d6.
δ 10.8, 22.0, 31.7, 179.0
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Figure A42. 1H NMR (400 MHz) of 18 in DMSO-d6.
Contaminated with starting material, as evidenced by peaks at 2.93 and 2.06

147

Figure A43. 13C NMR (100 MHz) of 18 in DMSO-d6.
Contaminated with starting material.

Figure A44. FT-IR of 17 as a powder (ATR)
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Figure A45. FT-IR of 18 as a powder (ATR)

Figure A46. FT-IR of 20 as a powder (ATR)
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Figure A46. FT-IR of 21 as a powder (ATR)

Figure A47. FT-IR of 23 as a powder (ATR)
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Figure A48. FT-IR of 24 as a powder (ATR)

Figure A49. FT-IR of 25 as a powder (ATR)
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Figure A50. FT-IR of 26 as a powder (ATR)

Figure A51. FT-IR of 27 as a powder (ATR)
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Figure A52. 13C NMR (100 MHz) of 25 in DMSO-d6, inset shows DMSO.
δ 14.2, 14.9, 64.0, 110.0
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Figure A53. 1H NMR (400 MHz) of 26 in DMSO-d6.
δ 0.92 (t, 3H) 1.66 (br, 2H) 2.20 (s,3H) 2.22 (s,3H) 2.85 (s,3H) 4.21 (br,2H)7.48 (s, 1H).
Methanol present, peaks at 3.16 and 4.08.
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Figure A54. 13C NMR(100 MHz) of 26 in DMSO-d6, inset displays the DMSO.
δ 10.9, 14.9, 22.3, 69.7, 110.0
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Figure A55. 1H NMR (400MHz) of 27 in DMSO-d6.
δ 1.14 (t, 3H) 2.03 (s, 3H) 2.87 (s,3H) 4.08 (br, 2H) 7.45 (br, 5H) 7.61 (s, 1H)
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Figure A56. 13C NMR (100MHz) of 27 in DMSO-d6.
δ 14.8, 16.2, 110.0, 128.4, 129.5, 129.7, 132.9
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Figure A57. 1H NMR (400 MHz) of 22 in DMSO-d6.
δ 1.21 (t, 3H) 2.00 (s, 6H) 2.81(s, 3H) 4.20 (br, 2H) 8.03 (s, 1H)
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Figure A58. 1H NMR (400 MHz) of 23 in DMSO-d6.
δ 0.87 (t, 3H) 1.59 (br, 2H) 2.01 (br, 6H) 2.81 (s, 3H) 4.12 (br, 2H) 8.02 (s, 1H)
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Figure A59. 1H NMR (400 MHz) of 24 in DMSO-d6.
δ 1.12 (t, 3H) 1.80 (s, 3H) 2.85 (s, 3H) 7.46 (br, 5H) 8.19 (s, 1H)

Figure A60. Electronic spectra of Ni complexes 22 (blue trace), 23 (red trace), and 24
(black trace) in acetonitrile
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Figure A61. Electronic spectra of Zn complexes 25 (blue trace), 26 (red trace), and 27
(black trace) in acetonitrile
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Figure A62. MTT assay results of cell lines A549 (top) and IMR90 (bottom) for the free ligand
H2ATSM (black trace), CuATSM (red trace), Zn complex (blue trace), and NiATSM (green
trace).
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